var docs;if (!docs) docs =[]; docs["86"]={"8600":"<p><b>Title</b> Benzodiazepines / Teduglutide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Teduglutide may increase the serum concentration of Benzodiazepines. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients receiving benzodiazepines for evidence of toxicity following teduglutide initiation or dose increase.</p>\n<div>\n <p><b>Benzodiazepines Interacting Members</b> ALPRAZolam, Bromazepam, ChlordiazePOXIDE, CloBAZam, ClonazePAM, Clorazepate, DiazePAM, Estazolam, Ethyl Loflazepate, Etizolam, Flunitrazepam, Flurazepam, Loprazolam, LORazepam, Lormetazepam, Midazolam, Nitrazepam, Nordazepam, Oxazepam, Prazepam, Quazepam, Temazepam, Tofisopam, Triazolam</p>\n</div> \n<p><b>Discussion</b> According to teduglutide US prescribing information, treatment with teduglutide has been associated with altered mental status in patients receiving benzodiazepines.<sup>1</sup> One subject receiving prazepam experienced elevated prazepam concentrations (over 300 mcg/L) and coma within a week of teduglutide (0.05 mg/kg/day) initiation. Teduglutide may increase the rate and/or extent of benzodiazepine absorption.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Gattex</i> (teduglutide) [prescribing information]. Bedminster, NJ: NPS Pharmaceuticals, Inc; June 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8601":"<p><b>Title</b> Anticholinergic Agents / Mianserin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Mianserin may enhance the anticholinergic effect of Anticholinergic Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of increased anticholinergic effects if using mianserin together with drugs that have anticholinergic activity.</p>\n<div>\n <p><b>Anticholinergic Agents Interacting Members</b> Aclidinium, Acrivastine, Amitriptyline, Amoxapine, Atropine (Ophthalmic), Atropine (Systemic), Belladonna, Benperidol, Benztropine, Bilastine, Biperiden, Bromperidol, Brompheniramine, Buclizine, Carbinoxamine, Cetirizine (Systemic), Chlorpheniramine, ChlorproMAZINE, Cimetropium, Clemastine, Clidinium, ClomiPRAMINE, CloZAPine, Cyclizine, Cyclobenzaprine, Cyclopentolate, Cyproheptadine, Darifenacin, Desipramine, Dexbrompheniramine, Dexchlorpheniramine, Dicyclomine, DimenhyDRINATE, DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Disopyramide, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Fesoterodine, Fexofenadine, FlavoxATE, Flupentixol, FluPHENAZine, Glycopyrrolate (Oral Inhalation), Glycopyrrolate (Systemic), Haloperidol, Homatropine, HydrOXYzine, Hyoscyamine, Imidafenacin, Imipramine, Ipratropium (Nasal), Ipratropium (Oral Inhalation), Isocarboxazid, Ketotifen (Systemic), Levocetirizine, Lofepramine, Loratadine, Loxapine, Maprotiline, Meclizine, Melitracen [INT], Mepenzolate, Mequitazine, Methotrimeprazine, Methscopolamine, Methylene Blue, Moclobemide, Molindone, Nefopam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Orphenadrine, Oxatomide, Oxomemazine, Oxybutynin, Periciazine, Perphenazine, Phenelzine, Pheniramine, Phenyltoloxamine, Pimozide, Pizotifen, Prifinium, Prochlorperazine, Procyclidine, Promazine, Promethazine, Propantheline, Propiverine, Protriptyline, Pyrilamine (Systemic), QUEtiapine, QuiNIDine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Solifenacin, Syrian Rue, Thioridazine, Thiothixene, Thonzylamine, Tiotropium, Tiropramide, Tolterodine, Tranylcypromine, Trifluoperazine, Trihexyphenidyl, Trimeprazine, Trimethobenzamide, Trimipramine, Triprolidine, Trospium, Umeclidinium, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> According to the summary of product characteristics for multiple mianserin products, mianserin may enhance the anticholinergic actions of other drugs even though mianserin itself is not expected to exert a significant anticholinergic effect.<sup>1,2,3</sup><br><br>Studies of mianserin have similarly reported either only minimal anticholinergic activity (less than with the tricyclic antidepressant nortriptyline),<sup>4</sup> or no significant anticholinergic activity.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Mianserin [summary of product characteristics]. Eastbourne, East Sussex, United Kingdom: Teva UK Limited; April 2012.</p>\n<p>2. <i>Tolvon</i> (mianserin) [summary of product characteristics]. South Granville, New South Wales, Australia: Merck Sharpe &amp; Dohme (Australia) Pty Limited; December 2013.</p>\n<p>3. <i>Lumin</i> (mianserin) [summary of product characteristics]. Millers Point, New South Wales, Australia: Alphapharm Pty Limited; May 2013.</p>\n<p>4. Clemmesen L, Mikkelsen PL, Lund H, Bolwig TG, Rafaelsen OJ. Assessment of the anticholinergic effects of antidepressants in a single-dose cross-over study of salivation and plasma levels. <i>Psychopharmacology (Berl)</i>. 1984;82(4):348-354. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6427827\">[PubMed 6427827]</a></p>\n<p>5. Kopera H. Anticholinergic and blood pressure effects of mianserin, amitriptyline and placebo. <i>Br J Clin Pharmacol</i>. 1978;5 Suppl 1:29S-34S. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=341941\">[PubMed 341941]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8603":"<p><b>Title</b> Anticonvulsants / Mianserin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Mianserin may diminish the therapeutic effect of Anticonvulsants. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of decreased response to anticonvulsant therapy when used with mianserin. Some patients may require an increase in anticonvulsant dose.</p>\n<div>\n <p><b>Anticonvulsants Interacting Members</b> AcetaZOLAMIDE, Brivaracetam, CarBAMazepine, Divalproex, Eslicarbazepine, Ethosuximide, Ethotoin, Ezogabine, Felbamate, Fosphenytoin, Gabapentin, Lacosamide, LamoTRIgine, LevETIRAcetam, Methsuximide, OXcarbazepine, PENTobarbital, Perampanel, PHENobarbital, Phenytoin, Pregabalin, Primidone, Stiripentol, Sulthiame, Thiopental, TiaGABine, Topiramate, Valproic Acid and Derivatives, Vigabatrin, Zonisamide</p>\n</div> \n<p><b>Discussion</b> According to an animal study and the summary of product characteristics for multiple mianserin products, mianserin may decrease the seizure threshold, increasing the risk for a seizure, even in patients without a history of a seizure disorder.<sup>1,2,3,4</sup> The clinical significance of this is uncertain, but an increased dose of the anticonvulsant may be needed.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Tolvon</i> (mianserin) [summary of product characteristics]. South Granville, New South Wales, Australia: Merck Sharpe &amp; Dohme (Australia) Pty Limited; December 2013.</p>\n<p>2. <i>Lumin</i> (mianserin) [summary of product characteristics]. Millers Point, New South Wales, Australia: Alphapharm Pty Limited; May 2013.</p>\n<p>3. Mianserin [summary of product characteristics]. Eastbourne, East Sussex, United Kingdom: Teva UK Limited; April 2012.</p>\n<p>4. Borowicz KK, Banach M, Zarczuk R, Lukasik D, Luszczki JJ, Czuczwar SJ. Acute and chronic treatment with mianserin differentially affects the anticonvulsant activity of conventional antiepileptic drugs in the mouse maximal electroshock model. <i>Psychopharmacology (Berl)</i>. 2007;195(2):167-174. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17653694\">[PubMed 17653694]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8604":"<p><b>Title</b> Warfarin / PACLitaxel (Protein Bound)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> PACLitaxel (Protein Bound) may increase the serum concentration of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for increased warfarin effects (increased INR, bleeding) if paclitaxel is initiated.</p> \n<p><b>Discussion</b> One case report describes a 75-year-old female with stage IV ovarian cancer who was stabilized on warfarin 2 mg daily (INR 2.5-3.0).<sup>1</sup> Her INR rose to 5.2 after her first cycle of paclitaxel (175 mg/m<sup>2</sup>) and carboplatin. A post treatment rise in INR (range 3.3-4.5) was also observed after cycles 2 through 4. Empiric warfarin dose reductions were made prior to cycles 5 and 6 and the rise in INR post cycle was eliminated.<sup>1</sup> In contrast, a clinical study evaluated 25 patients with gynecological cancers who were receiving warfarin for the treatment of venous thromboembolism.<sup>2</sup> All patients then received neoadjuvant or adjuvant chemotherapy with low dose paclitaxel (80 mg/m<sup>2</sup>) and carboplatin on days 1, 8, and 15 of a 21 day cycle. An average of 4.6 cycles were completed per patient and no changes in INR or reports of bleeding were noted after any cycle.<sup>2</sup><br><br>The mechanism for this potential interaction is unknown, although both warfarin displacement from plasma proteins and competition for CYP 3A4 metabolism have been proposed.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Thompson ME, Highley MS. Interaction between paclitaxel and warfarin. <i>Ann Oncol</i>. 2003;14(3):500. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12598362\">[PubMed 12598362]</a></p>\n<p>2. Tabata T, Tanida K, Umekawa T, et al. Weekly low-dose paclitaxel and carboplatin therapy in gynecological cancer patients with venous thrombosis. <i>Anticancer Res</i>. 2008;28(6B):3971-3975. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19192658\">[PubMed 19192658]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8605":"<p><b>Title</b> Warfarin / PACLitaxel (Conventional)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> PACLitaxel (Conventional) may increase the serum concentration of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for increased warfarin effects (increased INR, bleeding) if paclitaxel is initiated.</p> \n<p><b>Discussion</b> One case report describes a 75-year-old female with stage IV ovarian cancer who was stabilized on warfarin 2 mg daily (INR 2.5-3.0).<sup>1</sup> Her INR rose to 5.2 after her first cycle of paclitaxel (175 mg/m<sup>2</sup>) and carboplatin. A post treatment rise in INR (range 3.3-4.5) was also observed after cycles 2 through 4. Empiric warfarin dose reductions were made prior to cycles 5 and 6 and the rise in INR post cycle was eliminated.<sup>1</sup> In contrast, a clinical study evaluated 25 patients with gynecological cancers who were receiving warfarin for the treatment of venous thromboembolism.<sup>2</sup> All patients then received neoadjuvant or adjuvant chemotherapy with low dose paclitaxel (80 mg/m<sup>2</sup>) and carboplatin on days 1, 8, and 15 of a 21 day cycle. An average of 4.6 cycles were completed per patient and no changes in INR or reports of bleeding were noted after any cycle.<sup>2</sup><br><br>The mechanism for this potential interaction is unknown, although both warfarin displacement from plasma proteins and competition for CYP 3A4 metabolism have been proposed.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Thompson ME, Highley MS. Interaction between paclitaxel and warfarin. <i>Ann Oncol</i>. 2003;14(3):500. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12598362\">[PubMed 12598362]</a></p>\n<p>2. Tabata T, Tanida K, Umekawa T, et al. Weekly low-dose paclitaxel and carboplatin therapy in gynecological cancer patients with venous thrombosis. <i>Anticancer Res</i>. 2008;28(6B):3971-3975. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19192658\">[PubMed 19192658]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8606":"<p><b>Title</b> Ruxolitinib / Fluconazole</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: Fluconazole should be avoided in doses over 200 mg/day, and in patients receiving ruxolitinib doses of 5 mg daily.</p></li>\n <li><p><b>Laboratory/Diagnostic Result</b>: Initiation of ruxolitinib for treatment of myelofibrosis should be avoided in patients with platelet counts less than 50*10<sup>9</sup>/L receiving fluconazole.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fluconazole may increase the serum concentration of Ruxolitinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid fluconazole doses over 200 mg/day in combination with ruxolitinib. In adult patients receiving fluconazole doses of 200 mg/day or less, initiate ruxolitinib for treatment of polycythemia vera at a dose of 5 mg twice daily. In patients receiving fluconazole doses of 200 mg/day or less, initiate ruxolitinib for treatment of myelofibrosis at a dose of 10 mg twice daily in with platelet counts 100*10<sup>9</sup>/L or greater, or 5 mg twice daily in those with platelet counts between 50*10<sup>9</sup>/L and 100*10<sup>9</sup>/L. In patients receiving established ruxolitinib doses, reduce ruxolitinib dose by 50% (rounded up to the nearest available tablet strength) if the previous dose was 10 mg twice daily or more, or reduce the dose to 5 mg once daily if the previous dose was 5 mg twice daily, following initiation of fluconazole at a dose of 200 mg/day or less. Avoid fluconazole in patients receiving established ruxolitinib doses of 5 mg daily.</p> \n<p><b>Discussion</b> Based on simulations summarized in ruxolitinib US prescribing information, coadministration with fluconazole100 mg daily or 400 mg daily is expected to increase the AUC of ruxolitinib by approximately 2 and 4 fold, respectively.<sup>1</sup> The expected mechanism of this interaction is fluconazole inhibition of ruxolitinib metabolism by CYP3A4 and CYP2C9. No clinical data are currently available.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Jakafi</i> (ruxolitinib) [prescribing information]. Wilmington, DE: Incyte Corporation; December 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8607":"<p><b>Title</b> Warfarin / Gemcitabine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Gemcitabine may enhance the anticoagulant effect of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients for increased warfarin effect (elevated INR, bleeding) if gemcitabine is initiated and monitor for decreased warfarin effects if gemcitabine is discontinued.</p> \n<p><b>Discussion</b> A case report describes a 63-year-old man stabilized on 57.5 mg/week of warfarin (INR 1.94).<sup>1</sup> He was started on 2 cycles of gemcitabine (2380 mg/week x 3 weeks then 2 weeks off) for the treatment of non-small cell lung cancer. After the first dose of gemcitabine, INR rose to 3.52 and his weekly warfarin dose was reduced to 52.5 mg/week. During cycle 2, his INR again rose after the first dose of gemcitabine to 3.58 and his weekly warfarin dose was further reduced to 48.5 mg/week. Gemcitabine was discontinued and subsequent INRs were subtherapeutic. His weekly warfarin dose was increased back to his baseline of 57.5 mg/week and his INR returned to the therapeutic range. There were no changes made to other concomitant medication therapy, but the patient's liver function tests (LFTs) rose more than 3-fold during treatment with gemcitabine.<sup>1</sup> Another report describes a 65-year-old man stablized on warfarin therapy (INR 1.94) who received gemcitabine (1000 mg/m<sup>2</sup>) and experienced more than a 6-fold increase in LFTs along with an INR of 8.0 and rectal bleeding.<sup>2</sup> A final report also describes a 70-year-old woman who experienced difficult to control INR values during treatment with gemcitabine and docetaxel, but details surrounding the dosing and timing of INR draws are not described making it difficult to draw any firm conclusions.<sup>3</sup> In contrast, the Eli Lilly safety database was searched through December 31, 2000, in order to identify interaction concerns with gemcitabine and anticoagulants.<sup>4</sup> It was reported that 5.4% (724/13,496) of reported adverse events involved the concomitant use of an anticoagulant but only 0.04% (6/13,496) involved a suspected drug interaction between the two agents.<sup>4</sup><br><br>The mechanism of this potential interaction is unknown, but gemcitabine induced liver dysfunction, leading to reduced warfarin requirements, has been proposed.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kinikar SA, Kolesar JM. Identification of a gemcitabine-warfarin interaction. <i>Pharmacotherapy</i>. 1999;19(11):1331-1333. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10555940\">[PubMed 10555940]</a></p>\n<p>2. Saif MW. Interaction between gemcitabine and warfarin causing gastrointestinal bleeding in a patient with pancreatic cancer. <i>J Appl Res</i>. 2005;5(3):434-437. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19829753\">[PubMed 19829753]</a></p>\n<p>3. Saif MW, Wasif N. Interaction between capecitabine and gemcitabine with warfarin in a patient with pancreatic cancer. <i>JOP</i>. 2008;9(6):739-743. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18981557\">[PubMed 18981557]</a></p>\n<p>4. Kilgour-Christie J, Czarnecki A. Gemcitabine and the interaction with anticoagulants. <i>Lancet Oncol</i>. 2002;3(8):460. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12147431\">[PubMed 12147431]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8608":"<p><b>Title</b> Idelalisib / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Idelalisib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of idelalisib with any strong CYP3A4 inducer.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> The idelalisib AUC and maximum serum concentration (Cmax) were an average of 75% and 58% lower, respectively, with the strong CYP3A4 inducer rifampin in a study of healthy volunteers who received single doses of idelalisib (150 mg) with or without concurrent rifampin (600 mg/day for 8 days).<sup>1</sup> The idelalisib prescribing information recommends avoiding concomitant use of idelalisib with strong inducers of CYP3A4.<br><br>The apparent mechanism of this interaction is induction of CYP3A4 (and possibly P-glycoprotein for many CYP3A inducers), resulting in decreased idelalisib concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Zydelig</i> (idelalisib) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; July 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8609":"<p><b>Title</b> Idelalisib / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Idelalisib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of idelalisib with St Johns wort.</p> \n<p><b>Discussion</b> Though specific data regarding St Johns wort and idelalisib are not available, the idelalisib prescribing information recommends avoiding concomitant use of idelalisib with strong inducers of CYP3A4 such as St Johns wort. The idelalisib AUC and maximum serum concentration (Cmax) were an average of 75% and 58% lower, respectively, with the strong CYP3A4 inducer rifampin in a study of healthy volunteers who received single doses of idelalisib (150 mg) with or without concurrent rifampin (600 mg/day for 8 days).<sup>1</sup> <br><br>The apparent mechanism of this interaction is induction of CYP3A4 (and possibly P-glycoprotein for many CYP3A inducers), resulting in decreased idelalisib concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Zydelig</i> (idelalisib) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; July 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8610":"<p><b>Title</b> CYP3A4 Substrates (High risk with Inhibitors) / Idelalisib</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Idelalisib may increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of idelalisib with CYP3A4 substrates.</p>\n<div>\n <p><b>CYP3A4 Substrates (High risk with Inhibitors) Interacting Members</b> Abemaciclib, Acalabrutinib, Ado-Trastuzumab Emtansine, Alfentanil, Alfuzosin, Alitretinoin (Systemic), ALPRAZolam, Amiodarone, AmLODIPine, Aprepitant, ARIPiprazole, ARIPiprazole Lauroxil, Asunaprevir, Atazanavir, AtorvaSTATin, Avanafil, Axitinib, Barnidipine, Benidipine, Benzhydrocodone, Blonanserin, Bosutinib, Brexpiprazole, Brigatinib, Bromocriptine, Bromperidol, Budesonide (Systemic), Buprenorphine, BusPIRone, Cabazitaxel, Cabozantinib, Calcitriol (Systemic), CarBAMazepine, Cariprazine, Ceritinib, ChlordiazePOXIDE, Chloroquine, Cilnidipine, Cilostazol, Cinacalcet, Cisapride, Citalopram, Clarithromycin, ClonazePAM, Cobimetinib, Colchicine, Conivaptan, Copanlisib, Crizotinib, CycloSPORINE (Systemic), Cyproterone, Dabrafenib, Daclatasvir, Dapoxetine, Darifenacin, Darunavir, Dasatinib, Deflazacort, Dexamethasone (Systemic), DiazePAM, Digitoxin, Dihydroergotamine, DilTIAZem, Disopyramide, DOCEtaxel, Domperidone, Doxazosin, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Dronedarone, Dydrogesterone, Ebastine, Elbasvir, Eletriptan, Eliglustat, Eplerenone, Ergoloid Mesylates, Ergonovine, Ergotamine, Erlotinib, Erythromycin (Systemic), Escitalopram, Eszopiclone, Ethosuximide, Etizolam, Everolimus, Felbamate, Felodipine, FentaNYL, Fesoterodine, Flibanserin, Flurazepam, Fluticasone (Oral Inhalation), Fosaprepitant, Gefitinib, Grazoprevir, GuanFACINE, Halofantrine, Haloperidol, HYDROcodone, HYDROXYprogesterone Caproate, Ibrutinib, Irinotecan (Conventional), Irinotecan (Liposomal), Isavuconazonium Sulfate, Isosorbide Dinitrate, Isosorbide Mononitrate, Isradipine, Itraconazole, Ivabradine, Ivacaftor, Ixabepilone, Ketamine, Lacidipine, Lapatinib, Lercanidipine, Levomilnacipran, Lidocaine (Systemic), Lidocaine (Topical), Lomitapide, Lovastatin, Lurasidone, Macitentan, Manidipine, Maraviroc, Mefloquine, Methadone, Methylergonovine, Midazolam, Midostaurin, MiFEPRIStone, Mirodenafil, Mirtazapine, Naloxegol, Nefazodone, Neratinib, NiCARdipine, NIFEdipine, Nilotinib, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Olaparib, Olmutinib, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, OxyCODONE, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Panobinostat, PAZOPanib, Pimavanserin, Pimozide, Piperaquine, Praziquantel, QUEtiapine, QuiNIDine, QuiNINE, Radotinib, Ranolazine, Reboxetine, Regorafenib, Ribociclib, Rupatadine, Ruxolitinib, Salmeterol, SAXagliptin, Sildenafil, Silodosin, Simeprevir, Simvastatin, Sirolimus, Solifenacin, Sonidegib, Stiripentol, SUFentanil, SUNItinib, Suvorexant, Tacrolimus (Systemic), Tadalafil, Tamoxifen, Tamsulosin, Telaprevir, Telithromycin, Temsirolimus, Teniposide, Tezacaftor, TiaGABine, Tofacitinib, Tolterodine, Tolvaptan, Trabectedin, TraZODone, Triazolam, Trimipramine, Udenafil, Valbenazine, Vardenafil, Vemurafenib, Venetoclax, Venlafaxine, Verapamil, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vinflunine, Vinorelbine, Zopiclone</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the idelalisib prescribing information, idelalisib (150 mg x 15 doses) increased the CYP3A4 substrate midazolam (5 mg single oral dose) AUC and maximum serum concentration 5.4-fold and 2.4-fold, respectively.<sup>1</sup> A case report describes a 71-year-old woman receiving diazepam, venlafaxine, and quetiapine (all CYP3A4 substrates) who experienced encephalopathy and respiratory acidosis 10 days after initiation of idelalisib (150 mg twice daily).<sup>2</sup> After discontinuing diazepam, venlafaxine, and idelalisib, encephalopathy and respiratory depression resolved. Idelalisib was resumed, diazepam was replaced with lorazepam, the venlafaxine dose was reduced, and she experienced no further adverse events.<sup>2</sup><br><br>Idelalisib prescribing information states that because idelalisib is a strong CYP3A4 inhibitor, it should not be used with CYP3A4 substrates.<sup>1</sup><br><br>Idelalisib-mediated inhibition of CYP3A4 is the likely mechanism for this interaction. CYP3A4 substrates most likely to be sensitive to this interaction are those that are highly dependent on CYP3A4 for their elimination and for which impaired metabolism may be clinically relevant.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Zydelig (idelalisib) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2014.</p>\n<p>2. Bossaer JB, Chakraborty K. Drug interaction between idelalisib and diazepam resulting in altered mental status and respiratory failure [published online May 26, 2016]. <i>J Oncol Pharm Pract</i>. Doi: 10.1177/1078155216653705. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27231113\">[PubMed 27231113]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8611":"<p><b>Title</b> Idelalisib / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Idelalisib. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor clinical response to idelalisib closely if used together with a strong CYP3A inhibitor. Patients experiencing significant adverse effects may require idelalisib dose modification.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> The AUC of idelalisib was an average of 1.8-fold higher with concurrent use of the strong CYP3A4 inhibitor ketoconazole (400 mg/day for 4 days) in a study of healthy volunteers who received single doses of idelalisib (400 mg) with or without ketoconazole.<sup>1</sup><br><br>The apparent mechanism of this interaction is inhibition of the CYP3A4-mediated metabolism of idelalisib, which is partially but not completely dependent on CYP3A, resulting in increased idelalisib concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Zydelig</i> (idelalisib) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; July 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8612":"<p><b>Title</b> Obinutuzumab / Agents with Antiplatelet Properties</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of bleeding and closely monitor platelet count during and immediately after therapy. Significant reductions in platelet counts may frequently be seen.</p>\n<div>\n <p><b>Agents with Antiplatelet Properties Interacting Members</b> Abciximab, Aceclofenac, Acemetacin, Anagrelide, Aspirin, Cangrelor, Cilostazol, Citalopram, Clopidogrel, Dapoxetine, Defibrotide, Desvenlafaxine, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dilazep, Dipyridamole, Dipyrone, DULoxetine, Eptifibatide, Escitalopram, Etodolac, Etofenamate, Fenoprofen, Floctafenine, FLUoxetine, Flurbiprofen (Systemic), FluvoxaMINE, Ibuprofen, Ibuprofen (Topical), Indobufen, Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Levomilnacipran, Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Milnacipran, Nabumetone, Naproxen, Oxaprozin, PARoxetine, Pelubiprofen, Phenylbutazone, Piracetam, Piroxicam (Systemic), Piroxicam (Topical), Prasugrel, Propyphenazone, Sarpogrelate, Sertraline, Sulfinpyrazone, Sulindac, Tenoxicam, Tiaprofenic Acid, Ticagrelor, Ticlopidine, Tirofiban, Tolfenamic Acid, Tolmetin, Triflusal, Venlafaxine, Vilazodone, Vorapaxar, Vortioxetine, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> Obinutuzumab prescribing information recommends careful consideration of withholding medications that may increase bleeding risk while taking obinutuzumab, particularly during the first cycle of treatment.<sup>1</sup> In clinical trials, grades 1-4 thrombocytopenia occurred in 15% of patients, with grades 3 and 4 thrombocytopenia occurring in 11% of patients.<sup>2</sup> Fatal hemorrhagic events during cycle 1 of treatment with obinutuzumab have also been reported.<br><br>More frequent monitoring and evaluation of hematologic status is recommended for individuals receiving anticoagulant therapy or drugs with antiplatelet activity concurrently with obinutuzumab therapy.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Gazyva (obinutuzumab). South San Francisco, CA: Genetech, Inc., June 2014.</p>\n<p>2. Lee HZ, Miller BW, Kwitkowski VE, et al. U.S. Food and Drug Administration Approval: Obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia. <i>Clin Cancer Res</i>. 2014;20:3902-3907. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24824310\">[PubMed 24824310]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8613":"<p><b>Title</b> Obinutuzumab / Anticoagulants</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Anticoagulants may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of bleeding and closely monitor platelet count during and immediately after therapy. Significant reductions in platelet counts may frequently be seen.</p>\n<div>\n <p><b>Anticoagulants Interacting Members</b> Acenocoumarol, Antithrombin, Apixaban, Argatroban, Bemiparin, Betrixaban, Bivalirudin, Dabigatran Etexilate, Dalteparin, Danaparoid, Desirudin, Edoxaban, Enoxaparin, Fondaparinux, Heparin, Nadroparin, Phenindione, Protein C Concentrate (Human), Rivaroxaban, Tinzaparin, Warfarin</p>\n</div> \n<p><b>Discussion</b> Obinutuzumab prescribing information recommends careful consideration of withholding medications that may increase bleeding risk while taking obinutuzumab, particularly during the first cycle of treatment.<sup>1</sup> In clinical trials, grades 1-4 thrombocytopenia occurred in 15% of patients, with grades 3 and 4 thrombocytopenia occurring in 11% of patients.<sup>2</sup> Fatal hemorrhagic events during cycle 1 of treatment with obinutuzumab have also been reported.<br><br>More frequent monitoring and evaluation of hematologic status is recommended for individuals receiving anticoagulant or antiplatelet therapy concurrently with obinutuzumab therapy.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Gazyva (obinutuzumab). South San Francisco, CA: Genetech, Inc., June 2014.</p>\n<p>2. Lee HZ, Miller BW, Kwitkowski VE, et al. U.S. Food and Drug Administration Approval: Obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia. <i>Clin Cancer Res</i>. 2014;20:3902-3907. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24824310\">[PubMed 24824310]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8630":"<p><b>Title</b> Efavirenz / Ginkgo Biloba</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ginkgo Biloba may decrease the serum concentration of Efavirenz. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased efavirenz serum concentrations and reduced effectiveness (eg, viral load, CD4 count) if <i>Ginkgo biloba</i> is used concomitantly with efavirenz.</p> \n<p><b>Discussion</b> Two case reports describe a potential interaction between efavirenz and <i>Ginkgo biloba</i>.<sup>1,2</sup> In the first case, a 47-year-old HIV positive man was taking efavirenz, emtricitabine, and tenofovir for 2 years with an undetectable viral load.<sup>1</sup> He developed a virologic failure after taking <i>Ginkgo biloba</i> for several months. Efavirenz plasma concentrations were determined from stored plasma samples prior to and during his <i>Ginkgo biloba</i> use. Concentrations of efavirenz decreased approximately 62% and coincided with an increase in viral load. Efavirenz was subsequently discontinued and no data with the removal of <i>Ginkgo biloba</i> was obtained.<sup>1</sup> In the second case, a 41-year-old HIV positive man was taking efavirenz, lamivudine, and zidovudine for 10 years with an undetectable viral load.<sup>2</sup> He experienced a virologic failure 2 months after beginning therapy with a nutritional supplement containing 300 mg of <i>Ginkgo biloba</i>. No plasma concentrations of efavirenz were obtained, but 1 month after discontinuation of the supplement (and continuation of efavirenz), he again obtained an undetectable viral load.<br><br>The mechanism of this potential interaction is unknown, but <i>Ginkgo biloba</i> has been shown to induce CYP3A4 in one,<sup>3</sup> but not another,<sup>4</sup> study. CYP3A4 is an enzyme at least partially responsible for efavirenz metabolism.<sup>5</sup> Due to the variability in natural products (eg, <i>Ginkgo biloba</i>), it is unknown if a particular formulation or dose is more susceptible to this interaction. As such, caution is warranted with combined use of efavirenz and any <i>Ginkgo biloba</i> product.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wiegman DJ, Brinkman K, Franssen EJ. Interaction of Ginkgo biloba with efavirenz. <i>AIDS</i>. 2009;23(9):1184-1185. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19451798\">[PubMed 19451798]</a></p>\n<p>2. Naccarato M, Yoong D, Gough K. A potential drug-herbal interaction between Ginkgo biloba and efavirenz. <i>J Int Assoc Physicians AIDS Care (Chic)</i>. 2012;11(2):98-100. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22323244\">[PubMed 22323244]</a></p>\n<p>3. Robertson SM, Davey RT, Voell J, Formentini E, Alfaro RM, Penzak SR. Effect of Ginkgo biloba extract on lopinavir, midazolam, and fexofenadine pharmacokinetics in healthy subjects. <i>Curr Med Res Opin</i>. 2008;24(2):591-599. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18205997\">[PubMed 18205997]</a></p>\n<p>4. Zadoyan G, Rokitta D, Klement S, et al. Effect of Ginkgo biloba special extract EGb 761 on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers. <i>Eur J Clin Pharmacol</i>.2012;68(5):553-560. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22189672\">[PubMed 22189672]</a></p>\n<p>5. <i>Sustiva</i> (efavirenz) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; May 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8631":"<p><b>Title</b> Digoxin / Antineoplastic Agents</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: This interaction appears to only apply to digoxin tablets. Other dosage forms (capsule, elixir) seem less susceptible to this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Antineoplastic Agents may decrease the serum concentration of Digoxin. Antineoplastic agents that cause significant mucositis/stomatitis may be more likely to impair digoxin tablet absorption. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Antineoplastic Agents Interacting Members</b> Amsacrine, AzaCITIDine, Belotecan, Bendamustine, Bleomycin, Busulfan, Cabazitaxel, Capecitabine, Carmustine, Chlorambucil, Clofarabine, Cyclophosphamide, Cytarabine (Conventional), DACTINomycin, DAUNOrubicin (Conventional), DAUNOrubicin (Liposomal), Decitabine, DOCEtaxel, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), EpiRUBicin, EriBULin, Etoposide, Etoposide Phosphate, Floxuridine, Fludarabine, Fluorouracil (Systemic), Fotemustine, Gemcitabine, Hydroxyurea, IDArubicin, Irinotecan (Conventional), Irinotecan (Liposomal), Ixabepilone, Lomustine, Mechlorethamine (Systemic), Melphalan, Mercaptopurine, Methotrexate, MitoMYcin (Systemic), MitoXANTRONE, Nelarabine, Oxaliplatin, PACLitaxel (Conventional), PACLitaxel (Protein Bound), PEMEtrexed, Pentostatin, Pixantrone, PRALAtrexate, Procarbazine, Raltitrexed, Tegafur, Temozolomide, Teniposide, Thioguanine, Topotecan, Trabectedin, Treosulfan, Vinflunine<br><b>Exceptions</b> Altretamine, CARBOplatin, CISplatin, Cladribine, Dacarbazine, Estramustine, Ifosfamide, Streptozocin, Thiotepa, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vindesine, Vinorelbine</p>\n</div> \n<p><b>Discussion</b> In one study, the pharmacokinetics of digoxin (0.5 mg tablet or 0.4 mg capsule) were assessed before and after treatment with high dose chemotherapeutic regimens in 13 patients.<sup>1</sup> Chemotherapeutic regimens consisted of high-dose carmustine, high-dose cyclophosphamide, or high-dose cytarabine and 7 subjects also received total body irradiation. After chemotherapy, the digoxin AUC decreased 44% in patients who received the tablets, while the AUC of digoxin was unchanged after chemotherapy in patients who received the capsules. The time to maximum serum concentration (Tmax) and the maximum serum concentration (Cmax) of digoxin were unchanged by chemotherapy for both the tablet and capsule formulations.<br><br>The mechanism of this interaction is unknown, but impaired digoxin absorption, due to damaged gastrointestinal mucosa caused by the chemotherapeutic regimens, has been proposed. Tablet formulations appear to be more affected, possibly due to delayed or impaired dissolution.<sup>2,3</sup> In support of this mechanism, one case report describes a 41-year-old woman who had undetectable serum digoxin levels after she received intestinal radiation despite taking 0.25 mg digoxin tablets daily for 2 weeks.<sup>2</sup> Only after increasing the digoxin dose and switching to an elixir were therapeutic digoxin levels achieved.<br><br>Of note, similar decreases in absorption have been seen with beta-acetyldigoxin (another cardiac glycoside) tablets after high-dose chemotherapy,<sup>4,5</sup> but digitoxin absorption appears to be unaffected by these ablative regimens.<sup>5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bjornsson TD, Huang AT, Roth P, Jacob DS, Christenson R. Effects of high-dose cancer chemotherapy on the absorption of digoxin in two different formulations. <i>Clin Pharmacol Ther</i>. 1986;39(1):25-28. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3943266\">[PubMed 3943266]</a></p>\n<p>2. Jusko WJ, Conti DR, Molson A, Kuritzky P, Giller J, Schultz R. Digoxin absorption from tablets and elixir. The effect of radiation-induced malabsorption. <i>JAMA</i>. 1974;230(11):1554-1555. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4479663\">[PubMed 4479663]</a></p>\n<p>3. Hall WH, Doherty JE. Tritiated digoxin. XXII. Absorption and excretion in malabsorption syndromes. <i>Am J Med</i>. 1974;56(4):437-442. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4818410\">[PubMed 4818410]</a></p>\n<p>4. Kuhlmann J, Zilly W, Wilke J. Effects of cytostatic drugs on plasma level and renal excretion of beta-acetyldigoxin. <i>Clin Pharmacol Ther</i>. 1981;30(4):518-527. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7285486\">[PubMed 7285486]</a></p>\n<p>5. Kuhlmann J. Inhibition of digoxin absorption but not of digitoxin during cytostatic drug therapy. <i>Arzneimittelforschung</i>. 1982;32(6):698-704. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6889430\">[PubMed 6889430]</a></p>\n<p>6. Kuhlmann J, Wilke J, Rietbrock N. Cytostatic drugs are without significant effect on digitoxin plasma level and renal excretion. <i>Clin Pharmacol Ther</i>. 1982;32(5):646-651. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6897028\">[PubMed 6897028]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8632":"<p><b>Title</b> Bradycardia-Causing Agents / Tofacitinib</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: The Canadian prescribing information identifies bradycardia (and the combined use with other bradycardia-causing agents) as a significant concern with the use of tofacitinib. There is no mention of this adverse event or potential interaction in US labeling.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Tofacitinib may enhance the bradycardic effect of Bradycardia-Causing Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for bradycardia and increases in PR interval if tofacitinib is combined with other bradycardia-causing agents.</p>\n<div>\n <p><b>Bradycardia-Causing Agents Interacting Members</b> Acebutolol, Ajmaline, Alectinib, Amiodarone, Arotinolol, Atenolol, Beractant, Betaxolol (Systemic), Bisoprolol, Bovine Lipid Extract Surfactant, Bovine Lung Extract, Brigatinib, Calfactant, Carteolol (Ophthalmic), Carvedilol, Celiprolol, Ceritinib, CloNIDine, Crizotinib, Dexmedetomidine, Digitoxin, Digoxin, DilTIAZem, Donepezil, Dronedarone, Esmolol, Fingolimod, Galantamine, Guanethidine, GuanFACINE, Ivabradine, Labetalol, Lanreotide, Levobunolol, Lofexidine, Lucinactant, Methyldopa, Metipranolol, Metoprolol, Moxonidine, Nadolol, Nebivolol, Octreotide, Oxprenolol, Pasireotide, Penbutolol, Pilsicainide, Pindolol, Poractant Alfa, Propafenone, Propranolol, Rilmenidine, Rivastigmine, Sotalol, SUFentanil, Timolol (Ophthalmic), Timolol (Systemic), TiZANidine, Verapamil</p>\n</div> \n<p><b>Discussion</b> According to the Canadian prescribing information, in placebo-controlled phase 2 clinical trials, treatment with tofacitinib 5 mg to 10 mg twice daily was associated with statistically significant 4 to 7 beats per minute decreases in heart rate and 4 to 10 millisecond increases in the PR interval compared with placebo.<sup>1</sup> As such, Canadian product labeling warns that caution should be observed if tofacitinib is combined with other medications that lower heart rate.<sup>1</sup> US labeling does not mention bradycardia or a prolonged PR interval as an observed adverse effect of tofacitinib and does not suggest additional monitoring when combined with other bradycardia-causing agents.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Xeljanz</i> (tofacitinib) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; April 2014.</p>\n<p>2. <i>Xeljanz</i> (tofacitinib) [prescribing information]. New York, NY: Pfizer Inc; March 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8633":"<p><b>Title</b> Olodaterol / Caffeine and Caffeine Containing Products</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Caffeine and Caffeine Containing Products may enhance the adverse/toxic effect of Olodaterol. Caffeine and Caffeine Containing Products may enhance the hypokalemic effect of Olodaterol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased effects of olodaterol (eg, hypokalemia, blood pressure/heart rate elevation) with concomitant use of caffeine.</p>\n<div>\n <p><b>Caffeine and Caffeine Containing Products Interacting Members</b> Caffeine, Kola Nut</p>\n</div> \n<p><b>Discussion</b> Olodaterol US prescribing information warns that concomitant treatment with xanthine derivatives may enhance the hypokalemic effects of olodaterol.<sup>1</sup> Increased sympathomimetic effects (eg, increases in blood pressure, heart rate) would be expected as well.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Striverdi Respimat</i> (olodaterol) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; July 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8634":"<p><b>Title</b> Olodaterol / Theophylline Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Theophylline Derivatives may enhance the adverse/toxic effect of Olodaterol. Theophylline Derivatives may enhance the hypokalemic effect of Olodaterol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased effects of olodaterol (eg, hypokalemia, blood pressure/heart rate elevation) with concomitant use of theophylline derivatives.</p>\n<div>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline, Dyphylline, Theophylline</p>\n</div> \n<p><b>Discussion</b> Olodaterol US prescribing information warns that concomitant treatment with xanthine derivatives may enhance the hypokalemic effects of olodaterol.<sup>1</sup> Increased sympathomimetic effects (eg, increases in blood pressure, heart rate) would be expected as well.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Striverdi Respimat</i> (olodaterol) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; July 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8636":"<p><b>Title</b> Bradycardia-Causing Agents / Bretylium</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Bretylium may enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use bretylium cautiously in combination with bradycardia-associated agents, monitoring for enhanced bradycardic effects and, when the bradycardia-associated agent is also an atrioventricular (AV) blocking agent, for enhanced AV blockade. Bretylium should only be used in cardiac glycoside-treated patients when other antiarrhythmic options are ineffective and when arrhythmia is not suspected to be related to digitalis toxicity.</p>\n<div>\n <p><b>Bradycardia-Causing Agents Interacting Members</b> Acebutolol, Ajmaline, Alectinib, Amiodarone, Arotinolol, Atenolol, Beractant, Betaxolol (Systemic), Bisoprolol, Bovine Lipid Extract Surfactant, Bovine Lung Extract, Brigatinib, Calfactant, Carteolol (Ophthalmic), Carvedilol, Celiprolol, Ceritinib, CloNIDine, Crizotinib, Dexmedetomidine, Digitoxin, Digoxin, DilTIAZem, Donepezil, Dronedarone, Esmolol, Fingolimod, Galantamine, Guanethidine, GuanFACINE, Ivabradine, Labetalol, Lanreotide, Levobunolol, Lofexidine, Lucinactant, Methyldopa, Metipranolol, Metoprolol, Moxonidine, Nadolol, Nebivolol, Octreotide, Oxprenolol, Pasireotide, Penbutolol, Pilsicainide, Pindolol, Poractant Alfa, Propafenone, Propranolol, Rilmenidine, Rivastigmine, Sotalol, SUFentanil, Timolol (Ophthalmic), Timolol (Systemic), TiZANidine, Verapamil</p>\n</div> \n<p><b>Discussion</b> The bretylium Canadian product monograph states that it may aggravate sinus bradycardia, prolong AV transmission in patients receiving atrioventricular (AV) blocking agents, worsen pre-existing AV blockade, and aggravate digitalis toxicity.<sup>1</sup> The mechanisms by which bretylium may exert these effects are unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bretylium tosylate [product monograph]. Boucherville, QC: Sandoz Canada Inc; March 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8637":"<p><b>Title</b> Digoxin / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may increase the serum concentration of Digoxin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased serum concentrations and toxicity of digoxin if cyclosporine is initiated.</p> \n<p><b>Discussion</b> One report describes two patients who experienced digoxin toxicity following initiation of cyclosporine.<sup>1,2</sup> The first patient was a 50-year-old man stabilized on digoxin 0.375 mg daily (serum levels 1.5 to 1.6 nmol/L) for the treatment of atrial fibrillation and congestive heart failure. Cyclosporine 400 mg twice daily was begun and he subsequently experienced nausea, vomiting, AV block and an accelerated junctional escape rhythm. His digoxin level was measured at 5.6 nmol/L while his renal function remained unchanged. The second patient was a 47-year-old man also taking digoxin 0.375 mg daily (serum levels 1.7 to 2.6 nmol/L). After initiation of cyclosporine 375 mg twice daily, he developed high grade AV block and his digoxin level was 10.6 nmol/L. His serum creatinine also doubled during this time.<sup>1,2</sup> <br><br>The same publication also describes a pharmacokinetic study in 2 patients that found intravenous digoxin clearance was reduced by approximately 50% after administration of cyclosporine.<sup>1,2</sup> The renal function of both patients also declined by more than 50% during the study. Another study evaluated 7 patients undergoing cardiac transplantation.<sup>3</sup> Digoxin (0.25 mg single intravenous dose) pharmacokinetics were measured prior to transplantation and cyclosporine therapy and compared to digoxin (0.5 mg single intravenous dose) pharmacokinetics just after transplantation. The half-life and volume of distribution of digoxin approximately doubled, but the clearance remained unchanged. Renal function (creatinine clearance) increased 23% after transplantation but did not reach statistical significance. Due to the numerous hemodynamic changes associated with transplantation, it is difficult to identify what role cyclosporine played in altering digoxin pharmacokinetics.<br><br>Prescribing information for both digoxin and cyclosporine warn that increased digoxin levels and toxicity have been seen when these agents are used concomitantly. Additional monitoring for digoxin toxicity, including serum level measurements, is warranted when these agents are combined.<sup>4,5</sup><br><br>The mechanism of this potential interaction likely relates to cyclosporine inhibition of P-glycoprotein (P-gp), <sup>6</sup> a major transporter responsible for digoxin efflux.<sup>4</sup> Greater changes in digoxin pharmacokinetics may be expected when digoxin is administered orally as P-gp in the gastrointestinal tract would also be inhibited by cyclosporine. Additionally, the nephrotoxicity associated with cyclosporine use may lead to digoxin accumulation and may be at least partially responsible for the results described in these case reports and pharmacokinetic studies.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Dorian P, Strauss M, Cardella C, David T, East S, Ogilvie R. Digoxin-cyclosporine interaction: severe digitalis toxicity after cyclosporine treatment. <i>Clin Invest Med</i>. 1988;11(2):108-112. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3396255\">[PubMed 3396255]</a></p>\n<p>2. Dorian P, Cardella C, Strauss M, David T, East S, Ogilvie R. Cyclosporine nephrotoxicity and cyclosporine-digoxin interaction prior to heart transplantation. <i>Transplant Proc</i>. 1987;19(1 pt 2): 1825-1827. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3274430\">[PubMed 3274430]</a></p>\n<p>3. Robieux I, Dorian P, Klein J, et al. The effects of cardiac transplantation and cyclosporine therapy on digoxin pharmacokinetics. <i>J Clin Pharmacol</i>. 1992;32(4):338-343. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1569236\">[PubMed 1569236]</a></p>\n<p>4. Digoxin [prescribing information]. Columbus, OH: Roxane Laboratories Inc; September 2012.</p>\n<p>5. <i>Sandimmune</i> (cyclosporine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; May 2013.</p>\n<p>6. Okamura N, Hirai M, Tanigawara Y, et al. Digoxin-cyclosporin A interaction: modulation of the multidrug transporter P-glycoprotein in the kidney. <i>J Pharmacol Exp Ther</i>. 1993;266(3):1614-1619. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8103797\">[PubMed 8103797]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8638":"<p><b>Title</b> Digoxin / ALPRAZolam</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> ALPRAZolam may increase the serum concentration of Digoxin. <b>Severity</b> Minor <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> One case report describes a 72-year old woman who experienced a nearly threefold increase in serum digoxin concentrations and developed ventricular tachycardia following the addition of alprazolam 1 mg daily to her longstanding digoxin regimen.<sup>1</sup> No changes in renal function or alterations to any other medications were observed. In a study of cardiac patients (N=12) taking digoxin 0.25 mg daily, administration of alprazolam 1 mg daily increased the digoxin AUC by approximately 66% in 3 elderly patients.<sup>2</sup> However, administration of alprazolam 0.5 mg daily had no effect on digoxin levels in the 3 other elderly patients in the study. Neither dose of alprazolam affected digoxin levels in the 6 patients less than 65 years of age.<sup>2</sup> Another pharmacokinetic study in 8 healthy volunteers found that alprazolam (1.5 mg/day) had no effect on the clearance, half-life, or total urinary excretion of digoxin (1.25 mg single intravenous dose).<sup>3</sup> One letter does report that digoxin (0.5 mg daily) half-life increased and urinary excretion decreased after coadministration with diazepam (5 mg every 12 hours for 2 doses).<sup>4</sup> However, the magnitude of the pharmacokinetic changes and statistical methods used are not described.<br><br>The mechanism of this potential interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Tollefson G, Lesar T, Grothe D, Garvey M. Alprazolam-related digoxin toxicity. <i>Am J Psychiatry</i>. 1984;141(12):1612-1613. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6150651\">[PubMed 6150651]</a></p>\n<p>2. Guven H, Tuncok Y, Guneri S, Cavdar C, Fowler J. Age-related digoxin-alprazolam interaction. <i>Clin Pharmacol Ther</i>. 1993;54(1):42-44. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8330464\">[PubMed 8330464]</a></p>\n<p>3. Ochs HR, Greenblatt DJ, Verburg-Ochs B. Effect of alprazolam on digoxin kinetics and creatinine clearance. <i>Clin Pharmacol Ther</i>. 1985;38(5):595-598. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2865030\">[PubMed 2865030]</a></p>\n<p>4. Castillo-Ferrando JR, Garcia M, Carmona J. Digoxin levels and diazepam. <i>Lancet</i>. 1980;2(8190):368. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6105500\">[PubMed 6105500]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8639":"<p><b>Title</b> Vitamin K Antagonists / Oritavancin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Oritavancin may increase the serum concentration of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use oritavancin cautiously in patients receiving vitamin K antagonists, and monitor closely for evidence of excessive anticoagulant effects (eg, easy bruising or bleeding). INR monitoring is unreliable within 12 hours of oritavancin administration.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study summarized in oritavancin US prescribing information, administration of oritavancin (1,200 mg single dose) increased the average AUC of warfarin by 31%.<sup>1</sup> The suspected primary mechanism of this interaction is oritavancin inhibition of CYP2C9 mediated warfarin metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Orbactiv (oritavancin) [prescribing information]. Parsippany, NJ: The Medicines Company; August 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8640":"<p><b>Title</b> Tricyclic Antidepressants / Levodopa</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Levodopa may enhance the adverse/toxic effect of Tricyclic Antidepressants. Specifically, the risk for EPS and/or hypertension may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Note that patients receiving this combination may be at greater risk for extrapyramidal symptoms (EPS) such as tardive dyskinesia, akinesia, and akathisia, as well as for increases in blood pressure. Advise patients to promptly report any signs or symptoms of unusual movements as well as any significant changes in blood pressure.</p>\n<div>\n <p><b>Tricyclic Antidepressants Interacting Members</b> Amitriptyline, Amoxapine, ClomiPRAMINE, Desipramine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine, Lofepramine, Melitracen [INT], Nortriptyline, Protriptyline, Trimipramine</p>\n</div> \n<p><b>Discussion</b> The carbidopa/levodopa prescribing information cautions that concurrent use with tricyclic antidepressants (TCAs) may be associated with extrapyramidal symptoms (EPS) and hypertension.<sup>1</sup> Specific data supporting this warning are not included in the prescribing information. Although levodopa treatment has commonly been associated with movement disorders such as dyskinesias,<sup>2</sup> and case reports have described EPS resulting from the use of TCAs,<sup>3,4</sup> published reports of any such reactions with the combination are lacking. Additionally, there are conflicting data/conclusions about any association between TCAs and EPS,<sup>5,6</sup> further questioning the significance of this potential risk.<br><br>The mechanism of this purported interaction resulting in EPS is not well understood, but it is believed to be due to a complex imbalance of dopamine, serotonin, and norepinephrine between cortical structures and the basal ganglia.<sup>6</sup><br><br>Details supporting the potential for increasing blood pressure with this combination are similarly lacking. One potential mechanism involves over-stimulation of peripheral alpha-adrenergic receptors, leading to excessive vasoconstriction, as both TCAs and levodopa (after conversion to dopamine) act as agonists at alpha-receptors.<sup>7,8</sup> Additionally, a potentiation of the pressor response of norepinephrine has been demonstrated with TCA administration, contributing to further vasoconstriction and subsequent hypertension.<sup>9</sup> The clinical significance of these mechanisms has not been proven.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Sinemet</i> (carbidopa levodopa) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; July 2014.</p>\n<p>2. Rascol O, Brooks DJ, Korczyn AD, et al. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. <i>Mov Disord</i>. 2006;21(11):1844-1850. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16958094\">[PubMed 16958094]</a></p>\n<p>3. Fann WE, Sullivan JL, Richman BW. Dyskinesias associated with tricyclic antidepressants. <i>Br J Psychiatry</i>. 1976;128:490-493. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1276554\">[PubMed 1276554]</a></p>\n<p>4. Vandel P, Bonin B, Leveque E, Sechter D, Bizouard P. Tricyclic antidepressant-induced extrapyramidal side effects. <i>Eur Neuropsychopharmacol</i>. 1997;7(3):207-212. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9213080\">[PubMed 9213080]</a></p>\n<p>5. Mamo DC, Sweet RA, Mulsant BH, et al. Effect of nortriptyline and paroxetine on extrapyramidal signs and symptoms: A prospective double-blind study in depressed elderly patients. <i>Am J Geriatr Psychiatry</i>. 2000;8(3):226-231. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10910421\">[PubMed 10910421]</a></p>\n<p>6. Gill HS, DeVane CL, Risch SC. Extrapyramidal symptoms associated with cyclic antidepressant treatment: A review of the literature and consolidating hypotheses. <i>J Clin Psychopharmacol</i>. 1997;17(5):377-389. [ PubMed 9315989]</p>\n<p>7. Messerli FH, Frohlich ED. High blood pressure: A side effect of drugs, poisons, and food. <i>Arch Intern Med</i>. 1979;139(6):682-687. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=375859\">[PubMed 375859]</a></p>\n<p>8. Goldberg LI. Dopamine receptors and hypertension: Physiologic and pharmacologic implications. <i>Am J Med</i>. 1984;77(4A):37-44. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6148892\">[PubMed 6148892]</a></p>\n<p>9. Prange AJ Jr, McCurdy RL, Cochrane CM. The systolic blood pressure response of depressed patients to infused norepinephrine. <i>J Psychiatr Res</i>. 1967;5(1):1-13. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20034172\">[PubMed 20034172]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8642":"<p><b>Title</b> Digoxin / QuiNINE</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> QuiNINE may increase the serum concentration of Digoxin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased serum concentrations/toxic effects of digoxin if quinine is initiated or the dose is increased.</p> \n<p><b>Discussion</b> Serum digoxin (0.25 mg daily) concentrations increased 63% in 4 normal subjects following a 4-day regimen of quinine (300 mg 4 times/day).<sup>1</sup> In another study, quinine (250 mg/day) increased digoxin (0.375 mg daily) concentrations by 25% (750 mg/day by 33%).<sup>2</sup> The total body clearance of digoxin (1 mg single intravenous dose) was decreased by 26% and the half-life increased 51% in 6 subjects following a 4-day course of quinine (200 mg every 8 hours).<sup>3</sup> The decrease in total body clearance appeared to be a result of a nonsignificant increase in renal clearance accompanied by a 55% decrease in nonrenal clearance. Similarly, digoxin (0.38 mg to 0.5 mg) nonrenal clearance decreased 34% with no change in renal clearance after treatment with quinine (250 mg three times daily x7 days) in 8 healthy volunteers.<sup>4</sup> A study described in the quinine prescribing information reported that in 4 healthy subjects who received digoxin (0.5 to 0.75 mg/day), treatment with quinine (750 mg/day) resulted in a 33% increase in digoxin AUC and a 35% reduction in the biliary clearance of digoxin.<sup>5</sup> In contrast, one letter briefly describes a study in which quinine (750 mg daily) had no effect on digoxin plasma concentrations in 17 patients.<sup>6</sup> The authors do note, however, that digoxin levels were markedly increased in 4 of the 17 subjects.<br><br>Quinine prescribing information recommends close monitoring of plasma digoxin concentrations if quinine and digoxin are used concomitantly.<sup>5</sup> Although not clearly established, quinine likely alters digoxin pharmacokinetics by reducing nonrenal (biliary) clearance due to its inhibitory effects on P-glycoprotein.<sup>5,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Aronson JK, Carver JG. Interaction of digoxin with quinine. <i>Lancet</i>. 1981;1(8235):1418. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6113370\">[PubMed 6113370]</a></p>\n<p>2. Pedersen KE, Lysgaard Madsen J, Klitgaard NA, Kjaer K, Hvidt S. Effect of quinine on plasma digoxin concentration and renal digoxin clearance. <i>Acta Med Scand</i>. 1985;218(2):229-232. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4061126\">[PubMed 4061126]</a></p>\n<p>3. Wandell M, Powell JR, Hager WD, et al. Effect of quinine on digoxin kinetics. <i>Clin Pharmacol Ther</i>. 1980;28(4):425-430. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7408402\">[PubMed 7408402]</a></p>\n<p>4. Hedman A, Angelin B, Arvidsson A, Dahlqvist R, Nilsson B. Interactions in the renal and biliary elimination of digoxin: steroselective difference between quinine and quinidine. <i>Clin Pharmacol Ther</i>. 1990;47(1):20-26. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2295215\">[PubMed 2295215]</a></p>\n<p>5. <i>Qualaquin</i> (quinine) [prescribing information]. Philadelphia PA: Mutual Pharmaceutical Company Inc; July 2014.</p>\n<p>6. Doering W. Is there a clinically relevant interaction between quinine and digoxin in human beings? <i>Am J Cardiol</i>. 1981;48(5):975-976. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7304446\">[PubMed 7304446]</a></p>\n<p>7. Hedman A. Inhibition by basic drugs of digoxin secretion into human bile. <i>Eur J Clin Pharmacol</i>. 1992;42(4):457-459. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1516611\">[PubMed 1516611]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8643":"<p><b>Title</b> MetFORMIN / Verapamil</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Verapamil may diminish the therapeutic effect of MetFORMIN. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Increase blood glucose concentration monitoring frequency in metformin-treated patients following verapamil initiation, discontinuation, or dose adjustment.</p> \n<p><b>Discussion</b> In a clinical study of 12 healthy volunteers, coadministration of sustained-release verapamil (180 mg/day for 3 days) had no impact on immediate-release metformin (1 g in the evening, then 750 mg at 8 AM the following day) pharmacokinetic variables but significantly reduced its glucose lowering effects following an oral glucose tolerance test (administered 2 hours after the second metformin dose).<sup>1</sup> The mechanism of this interaction is unclear. Verapamil may inhibit hepatic uptake of metformin by OCT1 and/or other transporters.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Cho SK, Kim CO, Park ES, Chung JY. Verapamil decreases the glucose-lowering effect of metformin in healthy volunteers [published online July 24, 2014]. <i>Br J Clin Pharmacol</i>. doi:10.1111/bcp.12476. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25060604\">[PubMed 25060604]</a></p>\n<p>2. Ahlin G, Chen L, Lazorova L, et al. Genotype-dependent effects of inhibitors of the organic cation transporter, OCT1: predictions of metformin interactions. <i>Pharmacogenomics J</i>. 2011;11(6):400-411. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20567254\">[PubMed 20567254]</a></p>\n<p>3. Ahlin G, Karlsson J, Pedersen JM, et al. Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. <i>J Med Chem</i>. 2008;51(19):5932-5942. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18788725\">[PubMed 18788725]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8644":"<p><b>Title</b> Lomitapide / Tipranavir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b> (Ritonavir): This interaction applies specifically to ritonavir-boosted tipranavir.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Tipranavir may increase the serum concentration of Lomitapide. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of lomitapide and strong CYP3A4 inhibitors, including tipranavir/ritonavir, is contraindicated.</p> \n<p><b>Discussion</b> According to lomitapide prescribing information, concomitant administration with strong CYP3A4 inhibitors, including tipranavir/ritonavir, is contraindicated.<sup>1</sup> Lomitapide exposure reportedly increased 27-fold when used with the strong CYP3A4 inhibitor ketoconazole.<sup>1</sup><br><br>Whether this concern is primarily related to tipranavir, ritonavir (which is used to “boost” tipranavir concentrations), or both is uncertain. The lomitapide prescribing information classifies tipranavir/ritonavir as a strong CYP3A4 inhibitor.<sup>1</sup> The degree to which tipranavir alone inhibits CYP3A4 is uncertain, but appears to be less substantial, as tipranavir alone may even induce CYP3A4.<sup>2</sup> Nevertheless, as tipranavir must always be given with ritonavir, the net effect is expected to be CYP3A4 inhibition.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Juxtapid</i> (lomitapide) [prescribing information]. Cambridge, MA: Aegerion Pharmaceuticals, Inc.; August 2014.</p>\n<p>2. Boehringer Ingelheim Pharmaceuticals Inc. Tipranavir: Anti-viral Drugs Advisory Committee (AVDAC) Briefing Document. NDA 21-814. http://www.fda.gov/ohrms/DOCKETS/ac/05/briefing/2005-4139b1-02-boehringer.pdf. Published April 19, 2005. Accessed June 4, 2014.</p>\n<p>3. <i>Aptivus</i> (tipranavir) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; April 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8645":"<p><b>Title</b> Losartan / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Losartan. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased losartan effects if rifampin is initiated and monitor for increased effects if rifampin is discontinued.</p> \n<p><b>Discussion</b> In a pharmacokinetic study in 10 healthy volunteers, the AUC of losartan (50 mg) and E3174 (the more potent active metabolite) decreased 36% and 41%, respectively, following a 7-day course of rifampin (300 mg daily).<sup>1</sup> The half-life of both losartan and E3174 was reduced approximately 50%. <br><br>The mechanism of this interaction has not been clearly established, but rifampin induction of CYP2C9 or CYP3A4 leading to increased clearance of losartan and E3174 has been proposed.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Williamson KM, Patterson JH, McQueen RH, Adams KF Jr, Pieper JA. Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. <i>Clin Pharmacol Ther</i>. 1998;63(3):316-323. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9542475\">[PubMed 9542475]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8646":"<p><b>Title</b> Rosuvastatin / Clopidogrel</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Clopidogrel may increase the serum concentration of Rosuvastatin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased toxicity of rosuvastatin (e.g., myalgia, rhabdomyolysis, liver function test abnormalities) in patients receiving clopidogrel. Rosuvastatin Canadian product labeling recommends limiting the rosuvastatin dose to a maximum of 20 mg/day in patients receiving clopidogrel.</p> \n<p><b>Discussion</b> In a clinical study of patients with stable coronary artery disease, administration of rosuvastatin (40 mg daily) during loading with clopidogrel (300 mg once, then 75 mg daily) was associated with a 96% increase in rosuvastatin AUC.<sup>1</sup> Similarly, the rosuvastatin Canadian product monograph reports that clopidogrel loading (300 mg once, then 75 mg 24 hours later) approximately doubled the rosuvastatin (20 mg single dose) AUC.<sup>2</sup> Coadministration of rosuvastatin (40 mg daily) after 1 week of clopidogrel (300 mg once, then 75 mg daily) was associated with only an approximately 40% increase in rosuvastatin AUC.<sup>1</sup><br><br>The mechanism of this interaction is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Pinheiro LF, Franca CN, Izar MC, et al. Pharmacokinetic interactions between clopidogrel and rosuvastatin: effects on vascular protection in subjects with coronary heart disease. <i>Int J Cardiol</i>. 2012;158(1):125-129. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22569318\">[PubMed 22569318]</a></p>\n<p>2. <i>Crestor</i> (rosuvastatin) [product monograph]. Mississauga, ON: AstraZeneca Canada Inc; July 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8647":"<p><b>Title</b> Aliskiren / Potassium Salts</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Potassium Salts may enhance the hyperkalemic effect of Aliskiren. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for signs and symptoms of hyperkalemia during concomitant use of aliskiren and potassium supplements.</p>\n<div>\n <p><b>Potassium Salts Interacting Members</b> Potassium Acetate, Potassium Chloride, Potassium Citrate, Potassium Gluconate, Potassium Iodate, Potassium Iodide, Potassium Phosphate</p>\n</div> \n<p><b>Discussion</b> The use of potassium supplements or potassium-containing salt substitutes by patients receiving aliskiren may increase the risk of developing hyperkalemia.<sup>1</sup> The risk is likely greatest in patients with additional risk factors for the development of hyperkalemia (eg, renal insufficiency, use of potassium-sparing diuretics).<sup>1</sup><br><br>This interaction is most likely the result of aldosterone suppression in patients receiving aliskiren, which may increase potassium retention.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Tekturna</i> (aliskiren) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8648":"<p><b>Title</b> Fosinopril / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antacids may decrease the serum concentration of Fosinopril. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The US and Canadian fosinopril manufacturer labels recommend separating the doses of antacids and fosinopril by 2 hours.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n</div> \n<p><b>Discussion</b> In a clinical study described in both the US and Canadian fosinopril product labeling, the coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and the urinary excretion of fosinoprilat (the active moiety of the prodrug fosinopril) compared with fosinopril administration alone.<sup>1,2</sup> No details of the study or magnitude of the pharmacokinetic changes were provided. The manufacturers recommend separating administration of fosinopril and antacids by 2 hours.<br><br>The mechanism of this potential interaction is unknown, but based on the manufacturer recommendation to separate administration (instead of avoiding all gastric acid suppression therapy), it may relate to direct inhibition of fosinopril absorption instead of reduced absorption due to elevated gastric pH.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Fosinopril [prescribing information]. Princeton, NJ: Sandoz Inc; May 2013.</p>\n<p>2. <i>Apo-fosinopril</i> (fosinopril) [product monograph]. Weston, Ontario, Canada: Apotex Inc; February 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8649":"<p><b>Title</b> Captopril / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antacids may decrease the serum concentration of Captopril. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased captopril effects if administered with antacids.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study, the maximum serum concentration (Cmax) and AUC of captopril (50 mg single dose) was reduced 50% and 42%, respectively, when coadministered with an antacid (aluminum hydroxide, magnesium hydroxide, and magnesium carbonate) in 10 healthy volunteers.<sup>1</sup> No changes in the hypotensive effect of captopril were observed.<br><br>The mechanism of this interaction is unknown, and the utility of separating the administration of captopril and antacids has not been evaluated.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mantyla R, Mannisto PT, Vuorela A, Sundberg S, Ottoila P. Impairment of captopril bioavailability by concomitant food and antacid intake. <i>Int J Clin Pharmacol Ther Toxicol</i>. 1984;22(11):626-629. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6389377\">[PubMed 6389377]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8650":"<p><b>Title</b> Dabigatran Etexilate / Ticagrelor</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Canadian product labeling recommends avoiding the combination of dabigatran and ticagrelor. US labeling warns of an interaction and increased bleeding risk, but does not recommend strict avoidance of this combination.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ticagrelor may enhance the anticoagulant effect of Dabigatran Etexilate. Ticagrelor may increase the serum concentration of Dabigatran Etexilate. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor closely for signs and symptoms of bleeding if dabigatran is used in combination with ticagrelor. Canadian product labeling recommends avoiding the concomitant use of these agents while US labeling makes no such recommendation.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the dabigatran product labeling, the administration of ticagrelor increased dabigatran plasma concentrations.<sup>1,2</sup> The magnitude of the increase appears dependent on the dose and timing of ticagrelor administration. The AUC and maximum serum concentration (Cmax) of dabigatran (110 mg twice daily) increased by 26% and 29%, respectively, when coadministered with ticagrelor 90 mg twice daily. The AUC and Cmax increased by 49% and 65% when coadministered with a ticagrelor loading dose of 180 mg. When the ticagrelor loading dose was given 2 hours after dabigatran, the AUC and Cmax increased by 27% and 24%, respectively.<sup>1,2</sup> Another study described only in the Canadian product label, reported that dabigatran (75 mg single dose) AUC increased by 73% and 56% after coadministration with a ticagrelor load (180 mg) and ticagrelor maintenance dosing (90 mg twice daily for multiple doses), respectively.<sup>2</sup> The Cmax increased by 95% with the ticagrelor load and 46% with ticagrelor maintenance dosing. <br><br>The mechanism for the observed pharmacokinetic interaction is unknown, but ticagrelor inhibition of P-glycoprotein may play a role.<sup>3</sup> <br><br>In addition to the increase in dabigatran exposure, the use of dabigatran in combination with any antiplatelet agent is expected to increase the risk of bleeding. In patients taking dabigatran for the treatment of atrial fibrillation, use of oral antiplatelet drugs was associated with a two-fold increase in major bleeding.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Pradaxa</i> (dabigatran etexilate) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; August 2014.</p>\n<p>2. <i>Pradaxa</i> (dabigatran etexilate) [product monograph]. Burlington, Ontario, Canada: Boehringer Ingelheim Canada Ltd; June 2014. </p>\n<p>3. Teng R, Butler K. A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers. <i>Eur J Clin Pharmacol</i>. 2013;69(10):1801-1808. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23748750\">[PubMed 23748750]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8651":"<p><b>Title</b> Digoxin / Eliglustat</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Eliglustat may increase the serum concentration of Digoxin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> In patients receiving digoxin, measure digoxin serum concentrations prior to initiating eliglustat. Preemptively reduce digoxin doses by 30% and continue monitoring following eliglustat initiation.</p> \n<p><b>Discussion</b> In a clinical study summarized in eliglustat US prescribing information, coadministration of eliglustat (127 mg twice daily in individuals considered CYP2D6 extensive or intermediate metabolizers, or 84 mg twice daily in those considered poor metabolizers) increased the average maximum concentration and AUC of eliglustat by approximately 1.7 and 1.5 fold, respectively.<sup>1</sup> The suspected primary mechanism of this interaction is eliglustat inhibition of P-glycoprotein mediated digoxin efflux.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Cerdelga</i> (eliglustat) [prescribing information]. Waterford, Ireland: Genzyme Ireland Ltd; August 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8652":"<p><b>Title</b> Ifosfamide / Aprepitant</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Aprepitant may increase the serum concentration of Ifosfamide. Specifically, concentrations of the toxic metabolites of ifosfamide may increase. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for ifosfamide neurotoxicity (eg, visual and auditory hallucinations, somnolence, confusion, delirium) if combined with aprepitant. Consider also monitoring for decreased ifosfamide efficacy.</p> \n<p><b>Discussion</b> Several case reports describe patients who developed what appears to be ifosfamide neurotoxicity (INT) with the concomitant use of aprepitant.<sup>1,2,3</sup> In all but one case, patients experienced INT when aprepitant was coadministered, but tolerated therapy without experiencing INT when ifosfamide was given without aprepitant. In one case, ifosfamide pharmacokinetic parameters were obtained with and without aprepitant coadministration.<sup>2</sup> After aprepitant exposure, ifosfamide serum levels decreased 15%, but the serum concentrations of the 2-dechloroethyl-ifosfamide (2d-Ifo), 3-dechloroethyl-ifosfamide (3d-Ifo), and 4-hydroxyl-ifosfamide (4OH-Ifo) metabolites increased 67%, 37%, and 28%, respectively.<sup>2</sup> The 2d-Ifo and 3d-Ifo metabolites are thought to be responsible for the neurotoxicity associated with ifosfamide use, while the 4OH-Ifo metabolite is the active alkylating agent of the parent drug ifosfamide.<sup>4</sup> <br><br>In contrast, a number of retrospective studies found no association between INT and aprepitant use.<sup>5,6,7</sup> One study did report a trend towards increased INT in patients who received aprepitant compared to those who did not (25% vs 9.5%), but it did not reach statistical significance.<sup>5</sup> The small sample sizes and/or low event rates in these analyses may have contributed to the observed results.<sup>5,6,7</sup><br><br>Product labeling for aprepitant and fosaprepitant warn that post-marketing experience has led to reports of INT when these agents are combined with ifosfamide.<sup>8,9</sup> <br><br>Although the mechanism of this potential interaction is unknown, aprepitant is known to both inhibit and induce CYP3A4.<sup>8,9</sup> It is proposed that the induction of CYP3A4 by aprepitant may increase the metabolism and formation of neurotoxic metabolites (2d-Ifo and 3d-Ifo) of ifosfamide.<sup>2</sup> In contrast, product labeling for ifosfamide warns that aprepitant may inhibit CYP3A4 and has the potential to decrease ifosfamide efficacy and toxicity.<sup>4</sup> Although published literature with this drug combination describes an increase in INT or no interaction, monitoring for decreased ifosfamide efficacy may also be warranted.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Shindorf ML, Manahan KJ, Geisler JP. The interaction of ifosfamide and aprepitant in gynecologic malignancies. <i>Gynecol Oncol Case Rep</i>. 2013;6:34-35. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24371715\">[PubMed 24371715]</a></p>\n<p>2. Durand JP, Gourmel B, Mir O, Goldwasser F. Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy. <i>Ann Oncol</i>. 2007;18(4):808-809. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17389531\">[PubMed 17389531]</a></p>\n<p>3. Jarkowski A 3rd. Possible contribution of aprepitant to ifosfamide-induced neurotoxicity. <i>Am J Health Syst Pharm</i>. 2008;65(23):2229-2231. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19020190\">[PubMed 19020190]</a></p>\n<p>4. <i>Ifex</i> (ifosfamide) [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; March 2012.</p>\n<p>5. Howell JE, Szabatura AH, Hatfield Seung A, Nesbit SA. Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant. <i>J Oncol Pharm Pract</i>. 2008;14(3):157-162. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18719071\">[PubMed 18719071]</a></p>\n<p>6. Hansen Ho, Yuen C. Aprepitant-associated ifosfamide neurotoxicity. <i>J Oncol Pharm Pract</i>. 2010;16(2):137-138. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19759053\">[PubMed 19759053]</a></p>\n<p>7. Szabatura AH, Cirrone F, Harris C, et al. An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center. [published online March 24, 2014]. <i>J Oncol Pharm Pract</i>. Doi: 10.1177/1078155214527143.<a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24664476\">[PubMed 24664476]</a></p>\n<p>8. <i>Emend</i> (aprepitant) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; August 2014.</p>\n<p>9. <i>Emend</i> (fosaprepitant dimeglumine) [prescribing information]. Whitehouse Station, NJ: Merck&amp; Co Inc; August 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8653":"<p><b>Title</b> Ifosfamide / Fosaprepitant</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosaprepitant may increase the serum concentration of Ifosfamide. Specifically, concentrations of the toxic metabolites of ifosfamide may increase. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for ifosfamide neurotoxicity (eg, visual and auditory hallucinations, somnolence, confusion, delirium) if combined with fosaprepitant. Consider also monitoring for decreased ifosfamide efficacy.</p> \n<p><b>Discussion</b> Several case reports describe patients who developed what appears to be ifosfamide neurotoxicity (INT) with the concomitant use of aprepitant (the active moiety of the prodrug fosaprepitant).<sup>1,2,3</sup> In all but one case, patients experienced INT when aprepitant was coadministered, but tolerated therapy without experiencing INT when ifosfamide was given without aprepitant. In one case, ifosfamide pharmacokinetic parameters were obtained with and without aprepitant coadministration.<sup>2</sup> After aprepitant exposure, ifosfamide serum levels decreased 15%, but the serum concentrations of the 2-dechloroethyl-ifosfamide (2d-Ifo), 3-dechloroethyl-ifosfamide (3d-Ifo), and 4-hydroxyl-ifosfamide (4OH-Ifo) metabolites increased 67%, 37%, and 28%, respectively.<sup>2</sup> The 2d-Ifo and 3d-Ifo metabolites are thought to be responsible for the neurotoxicity associated with ifosfamide use, while the 4OH-Ifo metabolite is the active alkylating agent of the prodrug ifosfamide.<sup>4</sup> <br><br>In contrast, a number of retrospective studies found no association between INT and aprepitant use.<sup>5,6,7</sup> One study did report a trend towards increased INT in patients who received aprepitant compared to those who did not (25% vs 9.5%), but it did not reach statistical significance.<sup>5</sup> The small sample sizes and/or low event rates in these analyses may have contributed to the observed results.<sup>5,6,7</sup><br><br>Product labeling for fosaprepitant and aprepitant warn that post-marketing experience has led to reports of INT when these agents are combined with ifosfamide.<sup>8,9</sup> <br><br>Although the mechanism of this potential interaction is unknown, aprepitant is known to both inhibit and induce CYP3A4.<sup>8,9</sup> It is proposed that the induction of CYP3A4 by aprepitant may increase the metabolism and formation of neurotoxic metabolites (2d-Ifo and 3d-Ifo) of ifosfamide.<sup>2</sup> In contrast, product labeling for ifosfamide warns that aprepitant may inhibit CYP3A4 and has the potential to decrease ifosfamide efficacy and toxicity.<sup>4</sup> Although published literature with this drug combination describes an increase in INT or no interaction, monitoring for decreased ifosfamide efficacy may also be warranted.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Shindorf ML, Manahan KJ, Geisler JP. The interaction of ifosfamide and aprepitant in gynecologic malignancies. <i>Gynecol Oncol Case Rep</i>. 2013;6:34-35. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24371715\">[PubMed 24371715]</a></p>\n<p>2. Durand JP, Gourmel B, Mir O, Goldwasser F. Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy. <i>Ann Oncol</i>. 2007;18(4):808-809. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17389531\">[PubMed 17389531]</a></p>\n<p>3. Jarkowski A 3rd. Possible contribution of aprepitant to ifosfamide-induced neurotoxicity. <i>Am J Health Syst Pharm</i>. 2008;65(23):2229-2231. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19020190\">[PubMed 19020190]</a></p>\n<p>4. <i>Ifex</i> (ifosfamide) [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; March 2012.</p>\n<p>5. Howell JE, Szabatura AH, Hatfield Seung A, Nesbit SA. Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant. <i>J Oncol Pharm Pract</i>. 2008;14(3):157-162. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18719071\">[PubMed 18719071]</a></p>\n<p>6. Hansen Ho, Yuen C. Aprepitant-associated ifosfamide neurotoxicity. <i>J Oncol Pharm Pract</i>. 2010;16(2):137-138. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19759053\">[PubMed 19759053]</a></p>\n<p>7. Szabatura AH, Cirrone F, Harris C, et al. An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center. [published online March 24, 2014]. <i>J Oncol Pharm Pract</i>. Doi: 10.1177/1078155214527143.<a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24664476\">[PubMed 24664476]</a></p>\n<p>8. <i>Emend</i> (aprepitant) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; August 2014.</p>\n<p>9. <i>Emend</i> (fosaprepitant dimeglumine) [prescribing information]. Whitehouse Station, NJ: Merck&amp; Co Inc; August 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8654":"<p><b>Title</b> Eliglustat / CYP2D6 Inhibitors (Strong)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: This combination should be avoided in patients considered extensive or intermediate CYP2D6 metabolizers who are also receiving a moderate or strong CYP3A4 inhibitor.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP2D6 Inhibitors (Strong) may increase the serum concentration of Eliglustat. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Reduce the eliglustat dose to 84 mg daily in patients also receiving strong CYP2D6 inhibitors. Use of eliglustat in combination with a strong CYP2D6 inhibitor and a strong or moderate CYP3A4 inhibitor should be avoided. Such use in patients considered extensive or intermediate CYP2D6 metabolizers is listed as contraindicated in US prescribing information.</p>\n<div>\n <p><b>CYP2D6 Inhibitors (Strong) Interacting Members</b> FLUoxetine, PARoxetine*, QuiNIDine, Tipranavir</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> According to eliglustat US prescribing information, coadministration with the strong CYP2D6 inhibitor paroxetine (30 mg daily) in 30 individuals considered CYP2D6 extensive metabolizers (EMs) increased the maximum concentration (Cmax) and AUC of eliglustat (84 mg twice daily) by 7.0 and 8.4 fold, respectively.<sup>1</sup> Pharmacokinetic simulations suggest that the Cmax and AUC of eliglustat may increase by: 2.1 and 2.3 fold, respectively, in individuals considered CYP2D6 intermediate metabolizers (Ims) receiving paroxetine; 3.8 and 4.5 fold, respectively, in Ems receiving the moderate CYP2D6 inhibitor terbinafine (note that terbinafine may act as a strong inhibitor under some circumstances);<sup>2</sup> 1.6 fold (both variables) in Ims receiving terbinafine; 16.7 and 24.2 fold, respectively, in Ems receiving paroxetine and the strong CYP3A4 inhibitor ketoconazole; 7.5 and 9.8 fold, respectively, in Ims receiving paroxetine and ketoconazole; 10.2 and 13.6 fold, respectively, in Ems receiving terbinafine and the moderate CYP3A4 inhibitor fluconazole; and 4.2 and 5.0 fold, respectively, in Ims receiving fluconazole and terbinafine.<sup>1</sup>.<br><br>The suspected primary mechanism of this interaction is inhibition of CYP2D6 mediated eliglustat metabolism. CYP2D6 and 3A4 are the primary metabolic pathways for eliglustat. Diminished CYP2D6 function, whether due to concomitant use of a CYP2D6 inhibitor or other factors (eg, genotype), is expected to increase the dependence of eliglustat metabolism on CYP3A4. Similarly, CYP3A4 inhibition is expected to increase the dependence of eliglustat metabolism on CYP2D6.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Cerdelga</i> (eliglustat) [prescribing information]. Waterford, Ireland: Genzyme Ireland Ltd; August 2014.</p>\n<p>2. Terbinafine [prescribing information]. Peachtree City, GA: Exelan Pharmaceuticals Inc; April 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8655":"<p><b>Title</b> Eliglustat / CYP2D6 Inhibitors (Moderate)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: This combination should be avoided in patients considered extensive or intermediate CYP2D6 metabolizers who are also receiving a moderate or strong CYP3A4 inhibitor.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Eliglustat. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Reduce the eliglustat dose to 84 mg daily in patients also receiving moderate CYP2D6 inhibitors. Use of eliglustat in combination with a moderate CYP2D6 inhibitor and a strong or moderate CYP3A4 inhibitor should be avoided. Such use in patients considered extensive or intermediate CYP2D6 metabolizers is listed as contraindicated in US prescribing information.</p>\n<div>\n <p><b>CYP2D6 Inhibitors (Moderate) Interacting Members</b> Abiraterone Acetate, Asunaprevir, BuPROPion, Cinacalcet, Darifenacin, Darunavir, DULoxetine, Lorcaserin, Mirabegron, Perhexiline, Rolapitant, Terbinafine (Systemic), Thioridazine</p>\n</div> \n<p><b>Discussion</b> According to eliglustat US prescribing information, coadministration with the strong CYP2D6 inhibitor paroxetine (30 mg daily) in 30 individuals considered CYP2D6 extensive metabolizers (EMs) increased the maximum concentration (Cmax) and AUC of eliglustat (84 mg twice daily) by 7.0 and 8.4 fold, respectively.<sup>1</sup> Pharmacokinetic simulations suggest that the Cmax and AUC of eliglustat may increase by: 2.1 and 2.3 fold, respectively, in individuals considered CYP2D6 intermediate metabolizers (Ims) receiving paroxetine; 3.8 and 4.5 fold, respectively, in Ems receiving the moderate CYP2D6 inhibitor terbinafine (note that terbinafine may act as a strong inhibitor under some circumstances);<sup>2</sup> 1.6 fold (both variables) in Ims receiving terbinafine; 16.7 and 24.2 fold, respectively, in Ems receiving paroxetine and the strong CYP3A4 inhibitor ketoconazole; 7.5 and 9.8 fold, respectively, in Ims receiving paroxetine and ketoconazole; 10.2 and 13.6 fold, respectively, in Ems receiving terbinafine and the moderate CYP3A4 inhibitor fluconazole; and 4.2 and 5.0 fold, respectively, in Ims receiving fluconazole and terbinafine.<sup>1</sup>.<br><br>The suspected primary mechanism of this interaction is inhibition of CYP2D6 mediated eliglustat metabolism. CYP2D6 and 3A4 are the primary metabolic pathways for eliglustat. Diminished CYP2D6 function, whether due to concomitant use of a CYP2D6 inhibitor or other factors (eg, genotype), is expected to increase the dependence of eliglustat metabolism on CYP3A4. Similarly, CYP3A4 inhibition is expected to increase the dependence of eliglustat metabolism on CYP2D6.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Cerdelga</i> (eliglustat) [prescribing information]. Waterford, Ireland: Genzyme Ireland Ltd; August 2014.</p>\n<p>2. Terbinafine [prescribing information]. Peachtree City, GA: Exelan Pharmaceuticals Inc; April 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8656":"<p><b>Title</b> Eliglustat / CYP3A4 Inhibitors (Strong)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: This combination should be avoided in patients also receiving a moderate or strong CYP2D6 inhibitor.</p></li>\n <li><p><b>Genotype</b>: This combination should be avoided in patients considered intermediate or poor CYP2D6 metabolizers.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eliglustat. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Reduce the eliglustat dose to 84 mg daily in patients considered extensive CYP2D6 metabolizers who also receive strong CYP3A4 inhibitors. Use of eliglustat in combination with a strong CYP3A4 inhibitor should be avoided in patients considered intermediate or poor CYP2D6 metabolizers, and in patients considered extensive CYP2D6 metabolizers who are also receiving moderate or strong CYP2D6 inhibitors; use under these circumstances is listed as contraindicated in US prescribing information.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic)*, Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> According to eliglustat US prescribing information, coadministration with the strong CYP3A4 inhibitor ketoconazole (400 mg daily) in 31 individuals considered CYP2D6 extensive metabolizers (EMs) increased the maximum concentration (Cmax) and AUC of eliglustat (84 mg twice daily) by 4.0 and 4.4 fold, respectively.<sup>1</sup> Pharmacokinetic simulations suggest that the Cmax and AUC of eliglustat may increase by: 4.4 and 5.4 fold, respectively, in individuals considered CYP2D6 intermediate metabolizers (Ims) receiving ketoconazole; 2.8 and 3.2 fold, respectively, in Ems receiving the moderate CYP3A4 inhibitor fluconazole; 2.5 and 2.9 fold, respectively, in Ims receiving fluconazole; 4.3 and 6.2 fold, respectively, in individuals considered CYP2D6 poor metabolizers (PMs) receiving ketoconazole (using eliglustat 84 mg daily); 2.4 and 3.0 fold, respectively, in PMs receiving ketoconazole (using eliglustat 84 mg daily); 16.7 and 24.2 fold, respectively, in Ems receiving ketoconazole and the strong CYP2D6 inhibitor paroxetine; 7.5 and 9.8 fold, respectively, in Ims receiving ketoconazole and paroxetine; 10.2 and 13.6 fold, respectively, in Ems receiving fluconazole and the moderate CYP2D6 inhibitor terbinafine (note that terbinafine may act as a strong inhibitor under some circumstances);<sup>2</sup> and 4.2 and 5.0 fold, respectively, in Ims receiving fluconazole and terbinafine.<sup>1</sup><br><br>The suspected primary mechanism of this interaction is inhibition of CYP3A4 mediated eliglustat metabolism. CYP2D6 and 3A4 are the primary metabolic pathways for eliglustat. Diminished CYP2D6 function, whether due to concomitant use of a CYP2D6 inhibitor or other factors (eg, genotype), is expected to increase the dependence of eliglustat metabolism on CYP3A4. Similarly, CYP3A4 inhibition is expected to increase the dependence of eliglustat metabolism on CYP2D6.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Cerdelga</i> (eliglustat) [prescribing information]. Waterford, Ireland: Genzyme Ireland Ltd; August 2014.</p>\n<p>2. Terbinafine [prescribing information]. Peachtree City, GA: Exelan Pharmaceuticals Inc; April 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8657":"<p><b>Title</b> Eliglustat / CYP3A4 Inhibitors (Moderate)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: This combination should be avoided in patients also receiving a moderate or strong CYP2D6 inhibitor.</p></li>\n <li><p><b>Genotype</b>: This combination should be avoided in patients considered intermediate or poor CYP2D6 metabolizers.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eliglustat. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Reduce the eliglustat dose to 84 mg daily in patients considered extensive CYP2D6 metabolizers who also receive moderate CYP3A4 inhibitors. Use of eliglustat in combination with a moderate CYP3A4 inhibitor should be avoided in patients considered intermediate or poor CYP2D6 metabolizers, and in patients considered extensive CYP2D6 metabolizers who are also receiving moderate or strong CYP2D6 inhibitors (use in this last setting is listed as contraindicated in US prescribing information).</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> According to eliglustat US prescribing information, coadministration with the strong CYP3A4 inhibitor ketoconazole (400 mg daily) in 31 individuals considered CYP2D6 extensive metabolizers (EMs) increased the maximum concentration (Cmax) and AUC of eliglustat (84 mg twice daily) by 4.0 and 4.4 fold, respectively.<sup>1</sup> Pharmacokinetic simulations suggest that the Cmax and AUC of eliglustat may increase by: 4.4 and 5.4 fold, respectively, in individuals considered CYP2D6 intermediate metabolizers (Ims) receiving ketoconazole; 2.8 and 3.2 fold, respectively, in Ems receiving the moderate CYP3A4 inhibitor fluconazole; 2.5 and 2.9 fold, respectively, in Ims receiving fluconazole; 4.3 and 6.2 fold, respectively, in individuals considered CYP2D6 poor metabolizers (PMs) receiving ketoconazole (using eliglustat 84 mg daily); 2.4 and 3.0 fold, respectively, in PMs receiving ketoconazole (using eliglustat 84 mg daily); 16.7 and 24.2 fold, respectively, in Ems receiving ketoconazole and the strong CYP2D6 inhibitor paroxetine; 7.5 and 9.8 fold, respectively, in Ims receiving ketoconazole and paroxetine; 10.2 and 13.6 fold, respectively, in Ems receiving fluconazole and the moderate CYP2D6 inhibitor terbinafine (note that terbinafine may act as a strong inhibitor under some circumstances);<sup>2</sup> and 4.2 and 5.0 fold, respectively, in Ims receiving fluconazole and terbinafine.<sup>1</sup><br><br>The suspected primary mechanism of this interaction is inhibition of CYP3A4 mediated eliglustat metabolism. CYP2D6 and 3A4 are the primary metabolic pathways for eliglustat. Diminished CYP2D6 function, whether due to concomitant use of a CYP2D6 inhibitor or other factors (eg, genotype), is expected to increase the dependence of eliglustat metabolism on CYP3A4. Similarly, CYP3A4 inhibition is expected to increase the dependence of eliglustat metabolism on CYP2D6.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Cerdelga</i> (eliglustat) [prescribing information]. Waterford, Ireland: Genzyme Ireland Ltd; August 2014.</p>\n<p>2. Terbinafine [prescribing information]. Peachtree City, GA: Exelan Pharmaceuticals Inc; April 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8658":"<p><b>Title</b> Eliglustat / CYP3A4 Inhibitors (Weak)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Genotype</b>: This combination should be avoided in patients considered poor CYP2D6 metabolizers.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Weak) may increase the serum concentration of Eliglustat. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action is needed under most circumstances. Use of eliglustat in combination with a weak CYP3A4 inhibitor should be avoided in patients considered poor CYP2D6 metabolizers.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Weak) Interacting Members</b> ALPRAZolam, Amiodarone, AmLODIPine, AtorvaSTATin, Bicalutamide, Bitter Orange, Cilostazol, Cimetidine, Ciprofloxacin (Systemic), Clotrimazole (Oral), CycloSPORINE (Systemic), Danazol, Dasatinib, Delavirdine, Everolimus, FluvoxaMINE, Fosaprepitant, Glecaprevir and Pibrentasvir, Goldenseal, Grazoprevir, Iloperidone, Isoniazid, Ivacaftor, Lapatinib, Lomitapide, Lurasidone, NiCARdipine, Palbociclib, PAZOPanib, Peppermint, Piperaquine, Propiverine, Propofol, QuiNIDine, Quinupristin, Ranolazine, Resveratrol, Roxithromycin, Ticagrelor, Tofisopam</p>\n</div> \n<p><b>Discussion</b> The potential interaction between weak CYP3A4 inhibitors and eliglustat has not been investigated. According to eliglustat US prescribing information, coadministration with the strong CYP3A4 inhibitor ketoconazole (400 mg daily) in 31 individuals considered CYP2D6 extensive metabolizers (EMs) increased the maximum concentration (Cmax) and AUC of eliglustat (84 mg twice daily) by 4.0 and 4.4 fold, respectively.<sup>1</sup> Pharmacokinetic simulations suggest that the Cmax and AUC of eliglustat may increase by: 4.4 and 5.4 fold, respectively, in individuals considered CYP2D6 intermediate metabolizers (Ims) receiving ketoconazole; 2.8 and 3.2 fold, respectively, in Ems receiving the moderate CYP3A4 inhibitor fluconazole;2.5 and 2.9 fold, respectively, in Ims receiving fluconazole; 4.3 and 6.2 fold, respectively, in individuals considered CYP2D6 poor metabolizers (PMs) receiving ketoconazole (using eliglustat 84 mg daily); 2.4 and 3.0 fold, respectively, in PMs receiving ketoconazole (using eliglustat 84 mg daily); 16.7 and 24.2 fold, respectively, in Ems receiving ketoconazole and the strong CYP2D6 inhibitor paroxetine; 7.5 and 9.8 fold, respectively, in Ims receiving ketoconazole and paroxetine; 10.2 and 13.6 fold, respectively, in Ems receiving fluconazole and the moderate CYP2D6 inhibitor terbinafine (note that terbinafine may act as a strong inhibitor under some circumstances);<sup>2</sup> and 4.2 and 5.0 fold, respectively, in Ims receiving fluconazole and terbinafine.<sup>1</sup><br><br>The suspected primary mechanism of this interaction is inhibition of CYP3A4 mediated eliglustat metabolism. CYP2D6 and 3A4 are the primary metabolic pathways for eliglustat. Diminished CYP2D6 function, whether due to concomitant use of a CYP2D6 inhibitor or other factors (eg, genotype), is expected to increase the dependence of eliglustat metabolism on CYP3A4. Similarly, CYP3A4 inhibition is expected to increase the dependence of eliglustat metabolism on CYP2D6.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Cerdelga (eliglustat) [prescribing information]. Waterford, Ireland: Genzyme Ireland Ltd; August 2014.</p>\n<p>2. Terbinafine [prescribing information]. Peachtree City, GA: Exelan Pharmaceuticals Inc; April 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8659":"<p><b>Title</b> Eliglustat / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of Eliglustat. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the use of grapefruit or grapefruit juice in combination with eliglustat, and advise patients to avoid this combination.</p> \n<p><b>Discussion</b> The potential interaction between grapefruit juice and eliglustat has not been investigated. However, grapefruit juice may increase eliglustat exposure based on its potential to act as a moderate or strong inhibitor of CYP3A4. According to eliglustat US prescribing information, coadministration with the strong CYP3A4 inhibitor ketoconazole (400 mg daily) in 31 individuals considered CYP2D6 extensive metabolizers (EMs) increased the maximum concentration (Cmax) and AUC of eliglustat (84 mg twice daily) by 4.0 and 4.4 fold, respectively.<sup>1</sup> Pharmacokinetic simulations suggest that the Cmax and AUC of eliglustat may increase by: 4.4 and 5.4 fold, respectively, in individuals considered intermediate CYP2D6 metabolizers (IMs) receiving ketoconazole; 2.8 and 3.2 fold, respectively, in EMs receiving the moderate CYP3A4 inhibitor fluconazole;2.5 and 2.9 fold, respectively, in IMs receiving fluconazole; 4.3 and 6.2 fold, respectively, in individuals considered CYP2D6 poor metabolizers (PMs) receiving ketoconazole (using eliglustat 84 mg daily); 2.4 and 3.0 fold, respectively, in PMs receiving ketoconazole (using eliglustat 84 mg daily); 16.7 and 24.2 fold, respectively, in EMs receiving ketoconazole and the strong CYP2D6 inhibitor paroxetine; 7.5 and 9.8 fold, respectively, in IMs receiving ketoconazole and paroxetine; 10.2 and 13.6 fold, respectively, in EMs receiving fluconazole and the moderate CYP2D6 inhibitor terbinafine (note that terbinafine may act as a strong inhibitor under some circumstances);<sup>2</sup> and 4.2 and 5.0 fold, respectively, in IMs receiving fluconazole and terbinafine.<sup>1</sup><br><br>The suspected primary mechanism of this interaction is inhibition of CYP3A4 mediated eliglustat metabolism. CYP2D6 and 3A4 are the primary metabolic pathways for eliglustat. Diminished CYP2D6 function, whether due to concomitant use of a CYP2D6 inhibitor or other factors (eg, genotype), is expected to increase the dependence of eliglustat metabolism on CYP3A4. Similarly, CYP3A4 inhibition is expected to increase the dependence of eliglustat metabolism on CYP2D6.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Cerdelga</i> (eliglustat) [prescribing information]. Waterford, Ireland: Genzyme Ireland Ltd; August 2014.</p>\n<p>2. Terbinafine [prescribing information]. Peachtree City, GA: Exelan Pharmaceuticals Inc; April 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8660":"<p><b>Title</b> Cabergoline / Clarithromycin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Clarithromycin may increase the serum concentration of Cabergoline. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased cabergoline effects and toxicities if combined with clarithromycin.</p> \n<p><b>Discussion</b> In a pharmacokinetic study conducted in 10 healthy volunteers, cabergoline (1 mg daily) 10 hour AUC and maximum serum concentration (Cmax) increased 162% and 176%, respectively, following treatment with clarithromycin (200 mg twice daily).<sup>1</sup> The report also describes 7 patients with Parkinson disease (PD) who were taking cabergoline. Upon addition of clarithromycin (400 mg twice daily), plasma concentrations 3 hours after cabergoline administration increased by 74%.<sup>1</sup> No increase in toxicities was noted in the 10 healthy volunteers or in 7 patients with PD with clarithromycin administration. However, in 3 patients with PD, an improvement in PD symptoms was seen.<sup>1</sup><br><br>The mechanism of this potential interaction is unknown. Cabergoline, unlike other ergot derivatives, does not undergo CYP mediated metabolism.<sup>2</sup>Although the interaction between CYP3A4 inhibitors (eg, clarithromycin) and ergot derivatives that rely on CYP3A4 for metabolism is fairly well documented,<sup>3,4,5,6</sup> it is unlikely to be the mechanism behind this observed interaction. Preliminary data suggest that cabergoline may be a substrate of P-glycoprotein,<sup>7</sup> a transporter clarithromycin is known to inhibit.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Nakatsuka A, Nagai M, Yabe H, et al. Effect of clarithromycin on the pharmacokinetics of cabergoline in healthy controls and patients with Parkinson's disease. <i>J Pharmacol Sci</i>. 2006;100(1):59-64. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16410677\">[PubMed 16410677]</a></p>\n<p>2. <i>Dostinex</i> (cabergoline) [prescribing information]. New York, NY: Pfizer Inc; August 2011.</p>\n<p>3. de Mey C, Althaus M, Ezan E, Retzow A. Erythromycin increases plasma concentrations of alpha-dihydroergocryptine in humans. <i>Clin Pharmacol Ther</i>. 2001;70(2):142-148. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11503008\">[PubMed 11503008]</a></p>\n<p>4. Nelson MV, Berchou RC, Kareti D, LeWitt PA. Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine. <i>Clin Pharmacol Ther</i>. 1990;47(6):694-697. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2357864\">[PubMed 2357864]</a></p>\n<p>5. Horowitz RS, Dart RC, Gomez HF. Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction. <i>Arch Intern Med</i>. 1996;156(4):456-458. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8607732\">[PubMed 8607732]</a></p>\n<p>6. Leroy F, Asseman P, Pruvost P, Adnet P, Lacroix D, Thery C. Dihydroergotamine-erythromycin-induced ergotism. <i>Ann Intern Med</i>. 1988;109(3):249. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3389610\">[PubMed 3389610]</a></p>\n<p>7. Athanasoulia AP, Sievers C, Ising M, et al. Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas. <i>Eur J Endocrinol</i>. 2012;167(3):327-335. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22672924\">[PubMed 22672924]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8661":"<p><b>Title</b> Eliglustat / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Eliglustat. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the use of eliglustat in combination with strong CYP3A4 inducers.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> According to eliglustat US prescribing information, coadministration of rifampin (600 mg daily) decreased the maximum concentration (Cmax) and AUC of eliglustat (127 mg twice daily) by approximately 90% in individuals considered extensive or intermediate CYP2D6 metabolizers.<sup>1</sup> In individuals considered CYP2D6 poor metabolizers, coadministration of rifampin (600 mg daily) decreased the Cmax and AUC of eliglustat (84 mg twice daily) by approximately 95%.<br><br>The suspected primary mechanism of this interaction is rifampin induction of CYP3A4 mediated eliglustat metabolism. CYP2D6 and 3A4 are the primary metabolic pathways for eliglustat. Diminished CYP2D6 function, whether due to concomitant use of a CYP2D6 inhibitor or other factors (eg, genotype), is expected to increase the dependence of eliglustat metabolism on CYP3A4.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Cerdelga</i> (eliglustat) [prescribing information]. Waterford, Ireland: Genzyme Ireland Ltd; August 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8662":"<p><b>Title</b> Eliglustat / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Eliglustat. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the use of eliglustat in combination with St. John's wort.</p> \n<p><b>Discussion</b> The potential interaction between St. John's wort and eliglustat has not been investigated. However, St. John's wort may decrease eliglustat exposure based on its potential to act as a moderate or strong inducer of CYP3A4. According to eliglustat US prescribing information, coadministration of the strong CYP3A4 inducer rifampin (600 mg daily) decreased the maximum concentration (Cmax) and AUC of eliglustat (127 mg twice daily) by approximately 90% in individuals considered extensive or intermediate CYP2D6 metabolizers.<sup>1</sup> In individuals considered poor CYP2D6 metabolizers, coadministration of rifampin (600 mg daily) decreased the Cmax and AUC of eliglustat (84 mg twice daily) by approximately 95%.<br><br>The suspected primary mechanism of this interaction is rifampin induction of CYP3A4 mediated eliglustat metabolism. CYP2D6 and 3A4 are the primary metabolic pathways for eliglustat. Diminished CYP2D6 function, whether due to concomitant use of a CYP2D6 inhibitor or other factors (eg, genotype), is expected to increase the dependence of eliglustat metabolism on CYP3A4.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Cerdelga</i> (eliglustat) [prescribing information]. Waterford, Ireland: Genzyme Ireland Ltd; August 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8663":"<p><b>Title</b> Cabergoline / Itraconazole</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Itraconazole may increase the serum concentration of Cabergoline. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for increased cabergoline effects and toxicities if combined with itraconazole.</p> \n<p><b>Discussion</b> One report describes two patients with Parkinson disease (PD) who experienced improvement in their symptoms after the addition of itraconazole to their cabergoline therapy.<sup>1</sup> In the first case, the patient was stabilized on cabergoline 4 mg daily and reported PD symptom improvement after being treated for a nail infection with itraconazole 200 mg twice daily for 1 week. The improvement in PD symptoms declined over a few weeks after itraconazole therapy was withdrawn. Improvement was again noted after 2 additional 1-week treatment courses of itraconazole. Before and after one of the itraconazole treatment courses, cabergoline plasma concentrations were obtained. The addition of itraconazole increased cabergoline concentrations by 300%. In the second case, a patient stabilized on cabergoline experienced toxicity in the form of hyperkinesia, requiring a cabergoline dose adjustment, after beginning therapy with itraconazole.<br><br>The mechanism of this potential interaction is unknown. Cabergoline, unlike other ergot derivatives, does not undergo CYP mediated metabolism.<sup>2</sup> Although the interaction between CYP3A4 inhibitors (eg, itraconazole) and ergot derivatives that rely on CYP3A4 for metabolism is fairly well documented,<sup>3,4,5,6</sup> it is unlikely to be the mechanism behind this observed interaction. Preliminary data suggest that cabergoline may be a substrate of P-glycoprotein,<sup>7</sup> a transporter itraconazole is known to inhibit.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Christensen J, Dupont E, Ostergaard K. Cabergoline plasma concentration is increased during concomitant treatment with itraconazole. <i>Mov Disord</i>. 2002;17(6):1360-1362. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12465083\">[PubMed 12465083]</a></p>\n<p>2. <i>Dostinex</i> (cabergoline) [prescribing information]. New York, NY: Pfizer Inc; August 2011.</p>\n<p>3. de Mey C, Althaus M, Ezan E, Retzow A. Erythromycin increases plasma concentrations of alpha-dihydroergocryptine in humans. <i>Clin Pharmacol Ther</i>. 2001;70(2):142-148. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11503008\">[PubMed 11503008]</a></p>\n<p>4. Nelson MV, Berchou RC, Kareti D, LeWitt PA. Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine. <i>Clin Pharmacol Ther</i>. 1990;47(6):694-697. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2357864\">[PubMed 2357864]</a></p>\n<p>5. Horowitz RS, Dart RC, Gomez HF. Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction. <i>Arch Intern Med</i>. 1996;156(4):456-458. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8607732\">[PubMed 8607732]</a></p>\n<p>6. Leroy F, Asseman P, Pruvost P, Adnet P, Lacroix D, Thery C. Dihydroergotamine-erythromycin-induced ergotism. <i>Ann Intern Med</i>. 1988;109(3):249. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3389610\">[PubMed 3389610]</a></p>\n<p>7. Athanasoulia AP, Sievers C, Ising M, et al. Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas. <i>Eur J Endocrinol</i>. 2012;167(3):327-335. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22672924\">[PubMed 22672924]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8664":"<p><b>Title</b> Etravirine / Boceprevir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: This interaction only applies if etravirine and boceprevir are combined with other agents that also reduce etravirine exposure (eg, darunavir/ritonavir, lopinavir/ritonavir, saquinavir/ritonavir, tenofovir, rifabutin)</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Boceprevir may decrease the serum concentration of Etravirine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the combination of etravirine and boceprevir if used with other agents that can reduce etravirine exposure. Etravirine and boceprevir can be combined without dose adjustment if other etravirine reducing agents are avoided.</p> \n<p><b>Discussion</b> In a clinical study described in the etravirine prescribing information, coadministration with boceprevir (800 mg three times daily) reduced etravirine maximum serum concentration (Cmax), AUC, and minimum serum concentration (Cmin) by 24%, 23%, and 29%, respectively.<sup>1</sup> <br><br>The prescribing information for etravirine states that this change in etravirine exposure is unlikely to be clinically significant and etravirine can be coadministered with boceprevir. However, the combination of etravirine and boceprevir should be avoided if it is also used with other agents that reduce etravirine exposure. Darunavir/ritonavir, lopinavir/ritonavir, saquinavir/ritonavir, tenofovir, and rifabutin are listed as agents that can reduce etravirine exposure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Intelence</i> (etravirine) [prescribing information]. Titusville, NJ: Janssen Products LP; August 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8665":"<p><b>Title</b> Suvorexant / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Suvorexant. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of suvorexant with strong CYP3A inhibitors.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> Suvorexant exposure increase by more than 2.5-fold following co-administration of suvorexant 40 mg with the strong CYP3A4 inhibitor ketoconazole (400 mg).<sup>1</sup> The suvorexant prescribing information recommends avoiding the concurrent use of suvorexant with strong CYP3A inhibitors.<sup>1</sup><br><br>Inhibition of the CYP3A-mediated metabolism of suvorexant is the likely mechanism for this interaction, as metabolism by CYP3A is the major elimination pathway for suvorexant.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Belsomra</i> (suvorexant) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; August 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8666":"<p><b>Title</b> HYDROcodone / CYP3A4 Inhibitors (Moderate)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: The significance of this interaction may be greater in patients who are also receiving a CYP2D6 inhibitor or with use of a CYP3A4 inhibitor that also inhibits CYP2D6, as CYP2D6 is partially responsible for hydrocodone metabolism.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of HYDROcodone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients for increased hydrocodone toxicities, including fatal respiratory depression, if combined with a moderate CYP3A4 inhibitor. Monitor patients at frequent intervals and consider hydrocodone dose reductions until stable drug effects are achieved.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> The prescribing information for at least one hydrocodone product (Zohydro ER) contains a boxed warning detailing that concomitant use of hydrocodone and any CYP3A4 inhibitor could result in an increase in hydrocodone plasma concentrations, since CYP3A4 plays a major role in hydrocodone metabolism.<sup>1</sup> This increase in plasma concentrations may prolong adverse drug effects and potentially lead to fatal respiratory depression. If coadministration of a CYP3A4 inhibitor and hydrocodone is necessary, monitor patients for sedation and respiratory depression at frequent intervals and consider hydrocodone dose reductions until stable drug effects are achieved.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Zohydro ER</i> (hydrocodone bitartrate) [prescribing information]. San Diego, CA: Zogenix Inc; August 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8669":"<p><b>Title</b> Suvorexant / CYP3A4 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Suvorexant. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The recommended dose of suvorexant is 5 mg/day in patients who are also receiving a moderate CYP3A4 inhibitor. The dose can be increased to 10 mg/day as needed. Caution patients about the potential for excessive sedation and a greater risk for next-day drowsiness.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> Suvorexant exposure increased by more than 2-fold with concomitant administration of the moderate CYP3A4 inhibitor diltiazem 240 mg.<sup>1</sup> Additionally, the prescribing information states that administration of 40 mg of suvorexant in non-elderly patients or 30 mg in elderly patients with diltiazem 240 mg is expected to exceed the predicted AUC upper boundary of clinical significance. However, concurrent administration of 20 mg of suvorexant with 240 mg of diltiazem resulted in a mean AUC and distribution largely contained within the clinical significance bounds in non-elderly subjects. Similar suvorexant exposure is expected with a 15 mg dose of suvorexant when coadministered with diltiazem. These boundaries were pre-determined by the study team to define the limits of a safe therapeutic range. Consequently, lower doses of suvorexant with moderate CYP3A4 inhibitors are expected to produce suvorexant plasma concentrations within the therapeutic window.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Belsomra</i> (suvorexant) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; August 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8670":"<p><b>Title</b> Suvorexant / CNS Depressants</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CNS Depressants may enhance the CNS depressant effect of Suvorexant. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Caution patients that the risk for significant CNS depression, including the risk for next day drowsiness, may be increased with concurrent use of suvorexant with other CNS depressants. Dose adjustment of suvorexant and/or any other CNS depressant may be necessary. The use of suvorexant with alcohol is specifically not recommended, and the suvorexant prescribing information also specifically recommends avoiding the concurrent use of other drugs to treat insomnia.</p>\n<div>\n <p><b>CNS Depressants Interacting Members</b> Acrivastine, Afloqualone, Alcohol (Ethyl), Alfentanil, ALPRAZolam, Amisulpride, Amitriptyline, Amobarbital, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Baclofen, Benperidol, Benzhydrocodone, Bilastine, Blonanserin, Brexpiprazole, Brimonidine (Ophthalmic), Brivaracetam, Bromazepam, Bromperidol, Brompheniramine, Buclizine, Buprenorphine, BusPIRone, Butabarbital, Butalbital, Butorphanol, CarBAMazepine, Carbinoxamine, Cariprazine, Carisoprodol, Cetirizine (Systemic), Chloral Betaine, Chloral Hydrate, ChlordiazePOXIDE, Chlormethiazole, Chlorpheniramine, ChlorproMAZINE, Chlorzoxazone, Cinnarizine, Clemastine, CloBAZam, ClomiPRAMINE, ClonazePAM, CloNIDine, Clorazepate, Clothiapine, CloZAPine, Codeine, Cyclizine, Cyclobenzaprine, Cyproheptadine, Dantrolene, Desflurane, Desipramine, Desloratadine, Deutetrabenazine, Dexbrompheniramine, Dexchlorpheniramine, DiazePAM, Difenoxin, Dihydrocodeine, DimenhyDRINATE, Dimethindene (Systemic), DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Diphenoxylate, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Efavirenz, Emedastine (Systemic), Entacapone, Eperisone, Estazolam, Eszopiclone, Ethosuximide, Ethotoin, Ethyl Loflazepate, Etizolam, Ezogabine, Felbamate, FentaNYL, Fexofenadine, Flibanserin, Flunarizine, Flunitrazepam, Flupentixol, FluPHENAZine, Flurazepam, Fosphenytoin, Gabapentin, Gabapentin Enacarbil, Glutethimide, GuanFACINE, Haloperidol, Halothane, Heroin, HYDROcodone, HYDROmorphone, HydrOXYzine, Iloperidone, Imipramine, Isoflurane, Ketamine, Ketotifen (Systemic), LamoTRIgine, LevETIRAcetam, Levocetirizine, Levorphanol, Lofepramine, Loprazolam, Loratadine, LORazepam, Lormetazepam, Loxapine, Lurasidone, Maprotiline, Meclizine, Melitracen [INT], Meperidine, Meprobamate, Meptazinol, Mequitazine, Metaxalone, Methadone, Methocarbamol, Methohexital, Methotrimeprazine, Methoxyflurane, Methsuximide, Mianserin, Midazolam, Mirtazapine, Molindone, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nalbuphine, Nalfurafine, Nefopam, Nitrazepam, Nitrous Oxide, Nordazepam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Opium, Opium Tincture, Orphenadrine, Oxatomide, Oxazepam, Oxomemazine, OxyCODONE, OxyMORphone, Paliperidone, Paraldehyde, Paregoric, Pentazocine, PENTobarbital, Perampanel, Periciazine, Perphenazine, Pheniramine, PHENobarbital, Phenyltoloxamine, Phenytoin, Pholcodine, Pimozide, Pipamperone [INT], Pipotiazine, Pizotifen, Pomalidomide, Prazepam, Pregabalin, Primidone, Prochlorperazine, Promazine, Promethazine, Propofol, Protriptyline, Pyrilamine (Systemic), Quazepam, QUEtiapine, Ramelteon, Remifentanil, Reserpine, Rilmenidine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Secobarbital, Sevoflurane, Sodium Oxybate, Stiripentol, SUFentanil, Sulpiride, Suvorexant, Tapentadol, Tasimelteon, Temazepam, Tetrabenazine, Thalidomide, Thiopental, Thioridazine, Thiothixene, Thonzylamine, TiaGABine, TiZANidine, Tofisopam, Tolcapone, Topiramate, TraMADol, Triazolam, Trifluoperazine, Trimeprazine, Trimipramine, Triprolidine, Valerian, Vigabatrin, Zaleplon, Ziconotide, Ziprasidone, Zolpidem, Zonisamide, Zopiclone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> The prescribing information for suvorexant cautions that concurrent use with other CNS depressants may result in enhanced CNS depression and may require dose adjustments of the other CNS depressant and/or suvorexant.<sup>1</sup> Additionally, CNS depressant effects may persist for up to several days in some patients after discontinuing suvorexant. Concurrent use of suvorexant with other CNS depressants may potentiate the risk of greater psychomotor impairment, next-day driving impairment, and complex behaviors such as “sleep driving”, etc.<sup>1</sup><br><br>The specific mechanism for this interaction appears to be additive or synergistic CNS depressant effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Belsomra</i> (suvorexant) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; August 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8671":"<p><b>Title</b> Suvorexant / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the CNS depressant effect of Suvorexant. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Patients should be advised not to consume alcohol in combination with suvorexant as such concurrent use is not recommended due to the risk for excessive CNS depressant effects.</p> \n<p><b>Discussion</b> The prescribing information for suvorexant recommends advising patients to avoid consuming alcohol in combination with suvorexant.<sup>1</sup> Risk of next-day impairment, nighttime “sleep-driving,” and other complex behaviors increases when suvorexant is used in combination with alcohol.<br><br>An additive effect on psychomotor performance was observed when a single dose of 40 mg of suvorexant was co-administered with a single dose of 0.7 g/kg of alcohol.<sup>1</sup> However, there were no alterations in the pharmacokinetics of suvorexant, and concentration of each agent was not significantly affected. The specific mechanism for this interaction appears to be additive or synergistic CNS depressant effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Belsomra</i> (suvorexant) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; August 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8672":"<p><b>Title</b> Suvorexant / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Suvorexant. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of decreased suvorexant effects if a strong CYP3A4 inducer is initiated/dose increased, and for increased effects if a CYP3A4 inducer is discontinued/dose decreased.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> Suvorexant exposure was decreased by 88% when suvorexant (40 mg) was co-administered with the strong CYP3A inducer rifampin (600 mg).<sup>1,2</sup> <br><br>The proposed mechanism for this interaction is induction of CYP3A4, leading to increased metabolism of suvorexant and potentially sub-therapeutic plasma concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Merck Sharp &amp; Dohme Corporation. Suvorexant Advisory Committee Meeting Briefing Document. NDA 204569. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/peripheralandcentralnervoussystemdrugsadvisorycommittee/ucm352970.pdf. Published May 22, 2013. Accessed August 27, 2014.</p>\n<p>2. <i>Belsomra</i> (suvorexant) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; August 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8673":"<p><b>Title</b> Digoxin / Suvorexant</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Suvorexant may increase the serum concentration of Digoxin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> An approximate 25% increase in digoxin AUC was observed when 40 mg of suvorexant was co-administered with 0.5 mg of digoxin.<sup>1</sup> Of note, the suvorexant dose used in this study was considerably higher than the maximum recommended dose of 20 mg. Inhibition of intestinal p-glycoprotein is thought to be the main mechanism of this interaction. Results from phase 3 clinical trials and in vitro studies show that suvorexant is a weak inhibitor of both CYP3A4 and intestinal p-glycoprotein.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Belsomra</i> (suvorexant) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; August 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8674":"<p><b>Title</b> CYP3A4 Substrates (High risk with Inhibitors) / Suvorexant</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Suvorexant may increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>CYP3A4 Substrates (High risk with Inhibitors) Interacting Members</b> Abemaciclib, Acalabrutinib, Ado-Trastuzumab Emtansine, Alfentanil, Alfuzosin, Alitretinoin (Systemic), ALPRAZolam, Amiodarone, AmLODIPine, Aprepitant, ARIPiprazole, ARIPiprazole Lauroxil, Asunaprevir, Atazanavir, AtorvaSTATin, Avanafil, Axitinib, Barnidipine, Benidipine, Benzhydrocodone, Blonanserin, Bosutinib, Brexpiprazole, Brigatinib, Bromocriptine, Bromperidol, Budesonide (Systemic), Buprenorphine, BusPIRone, Cabazitaxel, Cabozantinib, Calcitriol (Systemic), CarBAMazepine, Cariprazine, Ceritinib, ChlordiazePOXIDE, Chloroquine, Cilnidipine, Cilostazol, Cinacalcet, Cisapride, Citalopram, Clarithromycin, ClonazePAM, Cobimetinib, Colchicine, Conivaptan, Copanlisib, Crizotinib, CycloSPORINE (Systemic), Cyproterone, Dabrafenib, Daclatasvir, Dapoxetine, Darifenacin, Darunavir, Dasatinib, Deflazacort, Dexamethasone (Systemic), DiazePAM, Digitoxin, Dihydroergotamine, DilTIAZem, Disopyramide, DOCEtaxel, Domperidone, Doxazosin, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Dronedarone, Dydrogesterone, Ebastine, Elbasvir, Eletriptan, Eliglustat, Eplerenone, Ergoloid Mesylates, Ergonovine, Ergotamine, Erlotinib, Erythromycin (Systemic), Escitalopram, Eszopiclone, Ethosuximide, Etizolam, Everolimus, Felbamate, Felodipine, FentaNYL, Fesoterodine, Flibanserin, Flurazepam, Fluticasone (Oral Inhalation), Fosaprepitant, Gefitinib, Grazoprevir, GuanFACINE, Halofantrine, Haloperidol, HYDROcodone, HYDROXYprogesterone Caproate, Ibrutinib, Irinotecan (Conventional), Irinotecan (Liposomal), Isavuconazonium Sulfate, Isosorbide Dinitrate, Isosorbide Mononitrate, Isradipine, Itraconazole, Ivabradine, Ivacaftor, Ixabepilone, Ketamine, Lacidipine, Lapatinib, Lercanidipine, Levomilnacipran, Lidocaine (Systemic), Lidocaine (Topical), Lomitapide, Lovastatin, Lurasidone, Macitentan, Manidipine, Maraviroc, Mefloquine, Methadone, Methylergonovine, Midazolam, Midostaurin, MiFEPRIStone, Mirodenafil, Mirtazapine, Naloxegol, Nefazodone, Neratinib, NiCARdipine, NIFEdipine, Nilotinib, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Olaparib, Olmutinib, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, OxyCODONE, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Panobinostat, PAZOPanib, Pimavanserin, Pimozide, Piperaquine, Praziquantel, QUEtiapine, QuiNIDine, QuiNINE, Radotinib, Ranolazine, Reboxetine, Regorafenib, Ribociclib, Rupatadine, Ruxolitinib, Salmeterol, SAXagliptin, Sildenafil, Silodosin, Simeprevir, Simvastatin, Sirolimus, Solifenacin, Sonidegib, Stiripentol, SUFentanil, SUNItinib, Suvorexant, Tacrolimus (Systemic), Tadalafil, Tamoxifen, Tamsulosin, Telaprevir, Telithromycin, Temsirolimus, Teniposide, Tezacaftor, TiaGABine, Tofacitinib, Tolterodine, Tolvaptan, Trabectedin, TraZODone, Triazolam, Trimipramine, Udenafil, Valbenazine, Vardenafil, Vemurafenib, Venetoclax, Venlafaxine, Verapamil, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vinflunine, Vinorelbine, Zopiclone</p>\n</div> \n<p><b>Discussion</b> The average AUC and maximum serum concentration (Cmax) of the model CYP3A4 substrate midazolam was increased by approximately 50% and 25%, respectively, following multiple doses of 2 mg oral when administered concurrently with suvorexant 80 mg.<sup>1</sup> There was no significant change in midazolam AUC or Cmax with single doses, however. Of note, the suvorexant dose used in this study was also considerably higher than the maximum recommended dose of 20 mg.<br><br>The likely mechanism of any interaction is suvorexant inhibition of CYP3A. Suvorexant is characterized as a weak, time-dependent CYP3A4 inhibitor.<sup>1</sup> The degree to which clinical doses of suvorexant would inhibit the metabolism of CYP3A substrates is not certain, but any such effect is expected to be minor.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Belsomra</i> (suvorexant) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; August 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8675":"<p><b>Title</b> Protirelin / Corticosteroids (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Corticosteroids (Systemic) may diminish the diagnostic effect of Protirelin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Corticosteroids (Systemic) Interacting Members</b> Beclomethasone (Systemic), Betamethasone (Systemic), Corticotropin, Cortisone, Deflazacort, Dexamethasone (Systemic), Fludrocortisone, Hydrocortisone (Systemic), MethylPREDNISolone, PrednisoLONE (Systemic), PredniSONE, Triamcinolone (Systemic)</p>\n</div> \n<p><b>Discussion</b> The protirelin Israeli summary of product characteristics states that several drugs and drug classes (eg, glucocorticoids, somatostatin analogs, dopamine, levodopa, bromocriptine, salicylates, morphine, barbiturates, and X-ray contrast media) may reduce the rise of thyroid stimulating hormone concentrations following protirelin administration.<sup>1</sup> Test interpretation is only rarely impaired by these interactions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Protirelin [summary of product characteristics]. Caesarea, Israel: Ferring Pharmaceuticals Ltd, April 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8676":"<p><b>Title</b> Protirelin / Somatostatin Analogs</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Somatostatin Analogs may diminish the diagnostic effect of Protirelin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Somatostatin Analogs Interacting Members</b> Lanreotide, Octreotide, Pasireotide, Somatostatin Acetate</p>\n</div> \n<p><b>Discussion</b> The protirelin Israeli summary of product characteristics states that several drugs and drug classes (eg, glucocorticoids, somatostatin analogs, dopamine, levodopa, bromocriptine, salicylates, morphine, barbiturates, and X-ray contrast media) may reduce the rise of thyroid stimulating hormone concentrations following protirelin administration.<sup>1</sup> Test interpretation is only rarely impaired by these interactions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Protirelin [summary of product characteristics]. Caesarea, Israel: Ferring Pharmaceuticals Ltd, April 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8677":"<p><b>Title</b> Protirelin / Anti-Parkinson Agents (Dopamine Agonist)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Anti-Parkinson Agents (Dopamine Agonist) may diminish the diagnostic effect of Protirelin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Anti-Parkinson Agents (Dopamine Agonist) Interacting Members</b> Amantadine, Apomorphine, Bromocriptine, Levodopa, Pergolide, Piribedil, Pramipexole, ROPINIRole, Rotigotine</p>\n</div> \n<p><b>Discussion</b> The protirelin Israeli summary of product characteristics states that several drugs and drug classes (eg, glucocorticoids, somatostatin analogs, dopamine, levodopa, bromocriptine, salicylates, morphine, barbiturates, and X-ray contrast media) may reduce the rise of thyroid stimulating hormone concentrations following protirelin administration.<sup>1</sup> Test interpretation is only rarely impaired by these interactions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Protirelin [summary of product characteristics]. Caesarea, Israel: Ferring Pharmaceuticals Ltd, April 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8678":"<p><b>Title</b> Protirelin / Salicylates</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Salicylates may diminish the diagnostic effect of Protirelin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Salicylates Interacting Members</b> Aminosalicylic Acid, Aspirin, Bismuth Subsalicylate, Choline Magnesium Trisalicylate, Choline Salicylate, Magnesium Salicylate, Salsalate, Sodium Salicylate, Triflusal</p>\n</div> \n<p><b>Discussion</b> The protirelin Israeli summary of product characteristics states that several drugs and drug classes (eg, glucocorticoids, somatostatin analogs, dopamine, levodopa, bromocriptine, salicylates, morphine, barbiturates, and X-ray contrast media) may reduce the rise of thyroid stimulating hormone concentrations following protirelin administration.<sup>1</sup> Test interpretation is only rarely impaired by these interactions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Protirelin [summary of product characteristics]. Caesarea, Israel: Ferring Pharmaceuticals Ltd, April 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8679":"<p><b>Title</b> Protirelin / Morphine (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Morphine (Systemic) may diminish the diagnostic effect of Protirelin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The protirelin Israeli summary of product characteristics states that several drugs and drug classes (eg, glucocorticoids, somatostatin analogs, dopamine, levodopa, bromocriptine, salicylates, morphine, barbiturates, and X-ray contrast media) may reduce the rise of thyroid stimulating hormone concentrations following protirelin administration.<sup>1</sup> Test interpretation is only rarely impaired by these interactions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Protirelin [summary of product characteristics]. Caesarea, Israel: Ferring Pharmaceuticals Ltd, April 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8680":"<p><b>Title</b> Protirelin / Barbiturates</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Barbiturates may diminish the diagnostic effect of Protirelin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Barbiturates Interacting Members</b> Amobarbital, Butabarbital, Butalbital, Methohexital, PENTobarbital, PHENobarbital, Primidone, Secobarbital, Thiopental</p>\n</div> \n<p><b>Discussion</b> The protirelin Israeli summary of product characteristics states that several drugs and drug classes (eg, glucocorticoids, somatostatin analogs, dopamine, levodopa, bromocriptine, salicylates, morphine, barbiturates, and X-ray contrast media) may reduce the rise of thyroid stimulating hormone concentrations following protirelin administration.<sup>1</sup> Test interpretation is only rarely impaired by these interactions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Protirelin [summary of product characteristics]. Caesarea, Israel: Ferring Pharmaceuticals Ltd, April 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8681":"<p><b>Title</b> Protirelin / Iodinated Contrast Agents</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Iodinated Contrast Agents may diminish the diagnostic effect of Protirelin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Iodinated Contrast Agents Interacting Members</b> Diatrizoate Meglumine, Diatrizoate Sodium, Ethiodized Oil, Iobitridol, Iodipamide Meglumine, Iodixanol, Iohexol, Iomeprol, Iopamidol, Iopromide, Iothalamate Meglumine, Ioversol, Ioxaglate Meglumine and Ioxaglate Sodium, Ioxitalamate Meglumine, Meglumine Iotroxate</p>\n</div> \n<p><b>Discussion</b> The protirelin Israeli summary of product characteristics states that several drugs and drug classes (eg, glucocorticoids, somatostatin analogs, dopamine, levodopa, bromocriptine, salicylates, morphine, barbiturates, and X-ray contrast media) may reduce the rise of thyroid stimulating hormone concentrations following protirelin administration.<sup>1</sup> Test interpretation is only rarely impaired by these interactions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Protirelin [summary of product characteristics]. Caesarea, Israel: Ferring Pharmaceuticals Ltd, April 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8682":"<p><b>Title</b> Protirelin / Gonadorelin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Gonadorelin may diminish the diagnostic effect of Protirelin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The protirelin Israeli summary of product characteristics states that several drugs and drug classes (eg, gonadorelin, estrogens, clomiphene, spironolactone, iodide, amiodarone, lithium, theophylline, metoclopramide, domperidone, sulpiride, chlorpromazine, haloperidol, and prostaglandins) may enhance the rise of thyroid stimulating hormone concentrations following protirelin administration.<sup>1</sup> Test interpretation is only rarely impaired by these interactions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Protirelin [summary of product characteristics]. Caesarea, Israel: Ferring Pharmaceuticals Ltd, April 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8683":"<p><b>Title</b> Protirelin / Estrogen Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Estrogen Derivatives may diminish the diagnostic effect of Protirelin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Estrogen Derivatives Interacting Members</b> Diethylstilbestrol, Estradiol (Systemic), Estradiol (Topical), Estriol (Systemic), Estriol (Topical), Estrogens (Conjugated A/Synthetic), Estrogens (Conjugated B/Synthetic), Estrogens (Conjugated/Equine, Systemic), Estrogens (Conjugated/Equine, Topical), Estrogens (Esterified), Estrone, Estropipate, Ethinyl Estradiol, Mestranol, Polyestradiol, Tibolone</p>\n</div> \n<p><b>Discussion</b> The protirelin Israeli summary of product characteristics states that several drugs and drug classes (eg, gonadorelin, estrogens, clomiphene, spironolactone, iodide, amiodarone, lithium, theophylline, metoclopramide, domperidone, sulpiride, chlorpromazine, haloperidol, and prostaglandins) may enhance the rise of thyroid stimulating hormone concentrations following protirelin administration.<sup>1</sup> Test interpretation is only rarely impaired by these interactions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Protirelin [summary of product characteristics]. Caesarea, Israel: Ferring Pharmaceuticals Ltd, April 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8684":"<p><b>Title</b> Protirelin / ClomiPHENE</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> ClomiPHENE may diminish the diagnostic effect of Protirelin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The protirelin Israeli summary of product characteristics states that several drugs and drug classes (eg, gonadorelin, estrogens, clomiphene, spironolactone, iodide, amiodarone, lithium, theophylline, metoclopramide, domperidone, sulpiride, chlorpromazine, haloperidol, and prostaglandins) may enhance the rise of thyroid stimulating hormone concentrations following protirelin administration.<sup>1</sup> Test interpretation is only rarely impaired by these interactions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Protirelin [summary of product characteristics]. Caesarea, Israel: Ferring Pharmaceuticals Ltd, April 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8685":"<p><b>Title</b> Protirelin / Spironolactone</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Spironolactone may diminish the diagnostic effect of Protirelin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The protirelin Israeli summary of product characteristics states that several drugs and drug classes (eg, gonadorelin, estrogens, clomiphene, spironolactone, iodide, amiodarone, lithium, theophylline, metoclopramide, domperidone, sulpiride, chlorpromazine, haloperidol, and prostaglandins) may enhance the rise of thyroid stimulating hormone concentrations following protirelin administration.<sup>1</sup> Test interpretation is only rarely impaired by these interactions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Protirelin [summary of product characteristics]. Caesarea, Israel: Ferring Pharmaceuticals Ltd, April 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8686":"<p><b>Title</b> Protirelin / Potassium Iodide</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Potassium Iodide may diminish the diagnostic effect of Protirelin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The protirelin Israeli summary of product characteristics states that several drugs and drug classes (eg, gonadorelin, estrogens, clomiphene, spironolactone, iodide, amiodarone, lithium, theophylline, metoclopramide, domperidone, sulpiride, chlorpromazine, haloperidol, and prostaglandins) may enhance the rise of thyroid stimulating hormone concentrations following protirelin administration.<sup>1</sup> Test interpretation is only rarely impaired by these interactions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Protirelin [summary of product characteristics]. Caesarea, Israel: Ferring Pharmaceuticals Ltd, April 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8687":"<p><b>Title</b> Protirelin / Amiodarone</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Amiodarone may diminish the diagnostic effect of Protirelin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The protirelin Israeli summary of product characteristics states that several drugs and drug classes (eg, gonadorelin, estrogens, clomiphene, spironolactone, iodide, amiodarone, lithium, theophylline, metoclopramide, domperidone, sulpiride, chlorpromazine, haloperidol, and prostaglandins) may enhance the rise of thyroid stimulating hormone concentrations following protirelin administration.<sup>1</sup> Test interpretation is only rarely impaired by these interactions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Protirelin [summary of product characteristics]. Caesarea, Israel: Ferring Pharmaceuticals Ltd, April 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8688":"<p><b>Title</b> Protirelin / Lithium</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Lithium may diminish the diagnostic effect of Protirelin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The protirelin Israeli summary of product characteristics states that several drugs and drug classes (eg, gonadorelin, estrogens, clomiphene, spironolactone, iodide, amiodarone, lithium, theophylline, metoclopramide, domperidone, sulpiride, chlorpromazine, haloperidol, and prostaglandins) may enhance the rise of thyroid stimulating hormone concentrations following protirelin administration.<sup>1</sup> Test interpretation is only rarely impaired by these interactions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Protirelin [summary of product characteristics]. Caesarea, Israel: Ferring Pharmaceuticals Ltd, April 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8689":"<p><b>Title</b> Protirelin / Theophylline Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Theophylline Derivatives may diminish the diagnostic effect of Protirelin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline, Dyphylline, Theophylline</p>\n</div> \n<p><b>Discussion</b> The protirelin Israeli summary of product characteristics states that several drugs and drug classes (eg, gonadorelin, estrogens, clomiphene, spironolactone, iodide, amiodarone, lithium, theophylline, metoclopramide, domperidone, sulpiride, chlorpromazine, haloperidol, and prostaglandins) may enhance the rise of thyroid stimulating hormone concentrations following protirelin administration.<sup>1</sup> Test interpretation is only rarely impaired by these interactions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Protirelin [summary of product characteristics]. Caesarea, Israel: Ferring Pharmaceuticals Ltd, April 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8690":"<p><b>Title</b> Protirelin / Metoclopramide</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Metoclopramide may diminish the diagnostic effect of Protirelin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The protirelin Israeli summary of product characteristics states that several drugs and drug classes (eg, gonadorelin, estrogens, clomiphene, spironolactone, iodide, amiodarone, lithium, theophylline, metoclopramide, domperidone, sulpiride, chlorpromazine, haloperidol, and prostaglandins) may enhance the rise of thyroid stimulating hormone concentrations following protirelin administration.<sup>1</sup> Test interpretation is only rarely impaired by these interactions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Protirelin [summary of product characteristics]. Caesarea, Israel: Ferring Pharmaceuticals Ltd, April 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8691":"<p><b>Title</b> Protirelin / Domperidone</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Domperidone may diminish the diagnostic effect of Protirelin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The protirelin Israeli summary of product characteristics states that several drugs and drug classes (eg, gonadorelin, estrogens, clomiphene, spironolactone, iodide, amiodarone, lithium, theophylline, metoclopramide, domperidone, sulpiride, chlorpromazine, haloperidol, and prostaglandins) may enhance the rise of thyroid stimulating hormone concentrations following protirelin administration.<sup>1</sup> Test interpretation is only rarely impaired by these interactions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Protirelin [summary of product characteristics]. Caesarea, Israel: Ferring Pharmaceuticals Ltd, April 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8692":"<p><b>Title</b> Protirelin / Sulpiride</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Sulpiride may diminish the diagnostic effect of Protirelin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The protirelin Israeli summary of product characteristics states that several drugs and drug classes (eg, gonadorelin, estrogens, clomiphene, spironolactone, iodide, amiodarone, lithium, theophylline, metoclopramide, domperidone, sulpiride, chlorpromazine, haloperidol, and prostaglandins) may enhance the rise of thyroid stimulating hormone concentrations following protirelin administration.<sup>1</sup> Test interpretation is only rarely impaired by these interactions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Protirelin [summary of product characteristics]. Caesarea, Israel: Ferring Pharmaceuticals Ltd, April 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8693":"<p><b>Title</b> Protirelin / ChlorproMAZINE</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> ChlorproMAZINE may diminish the diagnostic effect of Protirelin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The protirelin Israeli summary of product characteristics states that several drugs and drug classes (eg, gonadorelin, estrogens, clomiphene, spironolactone, iodide, amiodarone, lithium, theophylline, metoclopramide, domperidone, sulpiride, chlorpromazine, haloperidol, and prostaglandins) may enhance the rise of thyroid stimulating hormone concentrations following protirelin administration.<sup>1</sup> Test interpretation is only rarely impaired by these interactions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Protirelin [summary of product characteristics]. Caesarea, Israel: Ferring Pharmaceuticals Ltd, April 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8694":"<p><b>Title</b> Protirelin / Haloperidol</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Haloperidol may diminish the diagnostic effect of Protirelin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The protirelin Israeli summary of product characteristics states that several drugs and drug classes (eg, gonadorelin, estrogens, clomiphene, spironolactone, iodide, amiodarone, lithium, theophylline, metoclopramide, domperidone, sulpiride, chlorpromazine, haloperidol, and prostaglandins) may enhance the rise of thyroid stimulating hormone concentrations following protirelin administration.<sup>1</sup> Test interpretation is only rarely impaired by these interactions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Protirelin [summary of product characteristics]. Caesarea, Israel: Ferring Pharmaceuticals Ltd, April 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8695":"<p><b>Title</b> Protirelin / Alprostadil</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Alprostadil may diminish the diagnostic effect of Protirelin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The protirelin Israeli summary of product characteristics states that several drugs and drug classes (eg, gonadorelin, estrogens, clomiphene, spironolactone, iodide, amiodarone, lithium, theophylline, metoclopramide, domperidone, sulpiride, chlorpromazine, haloperidol, and prostaglandins) may enhance the rise of thyroid stimulating hormone concentrations following protirelin administration.<sup>1</sup> Test interpretation is only rarely impaired by these interactions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Protirelin [summary of product characteristics]. Caesarea, Israel: Ferring Pharmaceuticals Ltd, April 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8696":"<p><b>Title</b> Protirelin / Dinoprostone</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Dinoprostone may diminish the diagnostic effect of Protirelin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The protirelin Israeli summary of product characteristics states that several drugs and drug classes (eg, gonadorelin, estrogens, clomiphene, spironolactone, iodide, amiodarone, lithium, theophylline, metoclopramide, domperidone, sulpiride, chlorpromazine, haloperidol, and prostaglandins) may enhance the rise of thyroid stimulating hormone concentrations following protirelin administration.<sup>1</sup> Test interpretation is only rarely impaired by these interactions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Protirelin [summary of product characteristics]. Caesarea, Israel: Ferring Pharmaceuticals Ltd, April 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8697":"<p><b>Title</b> Protirelin / Carboprost Tromethamine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Carboprost Tromethamine may diminish the diagnostic effect of Protirelin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The protirelin Israeli summary of product characteristics states that several drugs and drug classes (eg, gonadorelin, estrogens, clomiphene, spironolactone, iodide, amiodarone, lithium, theophylline, metoclopramide, domperidone, sulpiride, chlorpromazine, haloperidol, and prostaglandins) may enhance the rise of thyroid stimulating hormone concentrations following protirelin administration.<sup>1</sup> Test interpretation is only rarely impaired by these interactions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Protirelin [summary of product characteristics]. Caesarea, Israel: Ferring Pharmaceuticals Ltd, April 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}